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Abstract
Diabetic ketoacidosis (DKA) is a state of severe insulin deficiency resulting in
hyperglycemia, ketoacidosis, and inflammation. Children with DKA have an increased risk
of microvascular complications (e.g. stroke). The glycocalyx maintains the anti-thrombotic
properties of endothelial cells (ECs), however the glycocalyx status is unknown in DKA.
We quantified major glycocalyx components: hyaluronic acid (HA), heparan sulfate (HS),
chondroitin sulfate (CS), and syndecan-1 in DKA plasma and correlated them with DKA
severity. HA/HS were significantly increased in the plasma of DKA patients in comparison
to insulin-controlled type-1 diabetics, but only HA correlated to DKA severity. Exogenous
addition or removal of HA increased reactive oxygen species generation, while only the
latter suppressed basal nitric oxide production in cerebral ECs, implicating a prothrombotic
endothelial response to HA shedding. Exogenous supplementation of HA/HS/CS reduced
platelet adhesion, suggesting shedding of HA/HS to be a contributor to the prothrombotic
state of DKA.

Keywords
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acid, heparan sulfate, plasma, nitric oxide, cerebral microvasculature, ROS production,
ERK2 signaling
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« Introduction »

1.1 « Type 1 Diabetes Mellitus »
Type 1 Diabetes Mellitus (T1DM) is a chronic condition that is usually diagnosed in
children, but can go asymptomatic until adolescence or early adult years87. T1DM is
normally characterized by the presence of autoantibodies targeting the production or the
release of insulin from ß-islet cells of the pancreas. In order to maintain their glucose levels
within a normal range (4-10 mmol/L in children, dependent on age), life-long usage of
exogenous insulin is required9. This differs from the more commonly diagnosed Type 2
Diabetes Mellitus (T2DM), where exogenous insulin cannot regulate their blood glucose
levels due to cells being insulin-resistant, rather than degeneration of the ß-islets87. Insulin
is a short peptide hormone that regulates the uptake of glucose into cells and is a key
maintainer of glucose homeostasis within the body87. There is also an idiopathic subset of
T1DM called Type 1B Diabetes Mellitus (T1BDM) where no circulating autoantibodies
can be found but the clinical symptoms of T1DM are seen7. Both T1BDM and T2DM tend
to affect older patients (> 20-30 years old), however T2DM incidence have recently seen an
increase in the younger population9. Onset of T1DM occurs most frequently during puberty
(10-14 years old), with more females being earlier diagnosed than males due to females
naturally maturing faster87. This disproportion balances out when looking at the adult
population of T1DM. All three types of DM commonly suffer from the lack of insulin
regulation causing endocrine and metabolic dysregulation between the fed and the fasted
state87.
The cohort of T1DM patients are affected by both genetic and environmental
influences on the risk of disease onset211,212. Researchers compared the haplotypes of
T1DM antigen presenting molecules, which is encoded on the human leukocyte antigen
(HLA) region on chromosome 6, to determine the genetic influence of T1DM. Two
haplotypes have been implicated as a major risk factor for T1DM and the development of
ß-cell autoantibodies, HLA-DR4-DQ8 and HLA-DR3-DQ2. HLA-DR4-DQ8 is associated
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with the development of autoantibodies targeted to the insulin pathway first, while HLADR3-DQ2 is associated with the development of glutamate decarboxylase 2 (GAD65, a
protein on insulin secretory vesicles) autoantibodies first16. The risk of T1DM within five
years of the first detected autoantibody related to insulin increases dramatically as more
unique autoantibodies targeting insulin production and secretion are found212. In
monozygous twin studies, it has been shown that having the haplotype only provided a
concordance of 30%, leading researchers to look at both the geographic and gestational
environment153. One of the most common countries with T1DM haplotypes is Sweden and
a study has shown that HLA-DR-DQ haplotypes who immigrated to Sweden had a higher
risk of disease onset, implicating environmental factors47. The amount of infections could
also determine disease onset as a study done in Russia showed that in similar riskhaplotype groups, children who had more infections over their lifetime had a lower risk of
developing autoantibodies towards insulin production and secretion93. Gestational events,
such as decreased choline-containing phospholipids in cord blood can also be a predictor of
T1DM development100.
The progression through T1DM can be separated into three stages. Stage 1 consists
of finding autoantibodies targeted to insulin or to any tyrosine phosphatase-like molecules
(e.g. GAD65, IA-2, or ZNT8) that are involved in secretion of vesicles from the ß-cells of
the pancreas87. Stage 2 occurs when blood glucose is elevated causing hyperglycemia, as
cells are not uptaking glucose from the blood due to the lack of circulating insulin. Stage 3
is when clinical onset of T1DM occurs with physical symptoms appearing such as
dehydration, polyuria, hyperglycemia, lack of insulin, and around 70-90% ß-cell loss due to
inflammatory responses from dendritic cells, T-cells, B-cells, and macrophages87,96. The
initial triggering event to activate autoantigens of the ß-cells is unknown but has been
suggested that onset can be triggered by viral and environmental events213. Both
autoantigen-specific CD4+ and CD8+ T-cells can be found within circulation and provoke
the response of further release and distribution of autoantibodies targeted to the ß-cells38.
Loss of heparan sulfate (HS), a component of the glycocalyx, in the basement membrane of
islets also correlated with ß-cell death in diabetic mice models, implicating a pathology of
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more than just auto-inflammation164. However, it is elusive as to whether chronic
inflammation or an episode of rapid ß-cell mass loss due to infiltrating inflammatory cells
are responsible for activating the clinical onset symptoms of T1DM87.
The development of insulin-based therapy vastly reduced mortality69 and healthcare
costs169 of T1DM as patients were able to manage their glucose levels and reduce metabolic
dysfunction episodes48. Consistent monitoring of glucose levels have developed insulin
pumps where insulin is automatically injected when needed, leading to improved glycemic
control and fewer hypoglycemic episodes11. Insulin treatment is also speculated to reduce
the immune response towards ß-cells post-treatment due to reduced production of insulin.
Unfortunately, T1DM patients are still at a 2-4 fold higher risk of death, mainly attributed
to increased risk of cardiovascular disease87. Consistently elevated glucose levels have been
associated with both chronic macrovascular and microvascular disease progression. The
macrovascular complications include increased risks of coronary heart disease, stroke,
cerebrovascular disease and peripheral artery disease180. Frequent hyperglycemia episodes
also partially contribute to the macrovascular complications by creating aversive osmotic
fluid loads on both the renal and heart systems over time. During hyperglycemia, an
overproduction of reactive oxygen species (ROS) also occurs due to a compensation
mechanism of the mitochondrial electron transport chain from hypoglycemic cells144.
Excessive ROS plays a deleterious role by reducing the responsiveness of the
microvasculature89, putting DM patients at higher risk for the development of nephropathy,
neuropathy and retinopathy87. Diabetic nephropathy occurs in 40% of T1DM, which is
initially indicated by microalbuminuria, an increase in albumin secretion152.
Microalbuminuria can proceed into macroalbuminuria, and then lead to chronic kidney
disease, or it can also regress to normoalbuminuria.

4

1.2 « Diabetic Ketoacidosis »
One of the highest risks of mortality can occur at the onset of T1DM, when the
patient is unaware they are no longer producing sufficient insulin, resulting in a metabolic
dysregulation and a lack of uptake of glucose within cells87. Diabetic ketoacidosis (DKA) is
a life-threatening condition that occurs when metabolic acidosis, hyperglycemia, and
ketonemia are simultaneously present in the patient. As glucose cannot be used as the
primary fuel, fats (e.g. lipids) are broken down to acetoacetic and ß-hydroxylbutyric acids
(ketones), which are naturally acidic, via lipolysis171. Excessive production of ketones
(ketonemia) also acidifies the blood and overloads the bicarbonate buffering capacity
causing ketoacidosis200. The lack of glucose uptake also switches muscles to anaerobic
metabolism leading to the production of acidic lactate, further disrupting the acid-base
homeostasis within the blood leading to metabolic acidosis35. The severity of the DKA
episode is determined by the level of acidity in the blood, with mild DKA having a venous
pH of 7.2-7.3, while moderate DKA has a pH of 7.1-7.2, and severe DKA has a pH of <
7.1200.
The body attempts to compensate for the lack of glucose within cells via
gluconeogenesis and glyconeolysis; both processes that exacerbate hyperglycemia as cells
are unable to uptake the glucose molecules from the blood without insulin171. The lack of
feedback from insulin to inhibit stress hormones such as glucagon, epinephrine, growth
hormone, and cortisol only further releases more glucose into the blood stream200. For
example, glucagon’s main function is to stimulate the production of ketone bodies in the
liver and increase hepatic glucose production to be secreted into the blood stream171.
Hyperglycemia also induces osmotic diuresis in the renal system. As more glucose is
secreted into the urinary system for excretion, not only is water osmotically drawn with
glucose; potassium, sodium, calcium, magnesium, chloride, and phosphate are also
excreted resulting in a net loss200. Along with the loss of previously mentioned ions, the
ketoanion excretion of excessive ketones require simultaneous cation excretion. As water
is lost, progressive volume depletion leads to decreased glomerular filtration, reduced
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glucose and ketone excretion, and exacerbation of the plasma tonicity imbalance171.
Presenting clinical symptoms would be dehydration, polyuria, vomiting, weakness,
abdominal pain, tachycardia, and Kussmaul breathing (deep respirations to eliminate blood
CO2)200. Eventually, the patient suffers reduced consciousness and enter a comatose state if
left untreated. Primary treatment goals are to restore circulatory fluid balance and infuse
insulin and electrolytes to treat hyperglycemia, hyperosmolality, and ionic imbalances171.

1.3 « Microvascular Dysfunction »
DKA patients account for over 1 billion in healthcare costs in the United States and
about 30% of newly diagnosed T1DM will experience a DKA episode145. DKA can be fatal
if treated late or due to secondary complications, including sepsis, pneumonia, acute
respiratory distress syndrome, cardiac arrhythmias, or rhabdomyolysis, which all contribute
to the mortality risk of DKA200. However, two of the major contributors to secondary
complications, cerebral edema (inflammatory response) and stroke (prothrombotic
response), involve microvascular dysfunction and are discussed below.

1.3.1

« Cerebral Edema »
Cerebral edema (CE) is one of the major microvascular dysfunctions in DKA

where the blood-brain barrier (BBB) permeability increases leading to fluid influx into the
extracellular space of the brain1,55,186. The incidence of CE occurs in 0.5-1% of DKA
episodes, but the mortality rate can climb to 24% in CE and even those who survive suffer
permanent neurological injury in 26% of the cases145,155. Initial CE seen in DKA patients
are considered vasogenic, where the loss of BBB integrity is facilitated by the DKAspecific inflammatory profile187,200. Increased glucose5, C-reactive protein53,98, and
ketone136 levels in the blood can create a proinflammatory cascade on endothelial cells
(ECs) to increase the permeability of the BBB over several months of hyperglycemia. DKA
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patients have a specific upregulation of cytokines (chemokine C-X-C motif ligand (CXCL)1, interleukin (IL)-8, IL-6, interferon (IFN) α-2)129, matrix metalloproteinases (MMP)
8/9202, and increased activation of polymorphonuclear neutrophils (PMNs)203, all capable of
causing cerebral endothelial dysfunction (CED) and endothelial injury contributing to the
vasogenic CE. These cytokines/MMPs can further elicit intracellular signaling, involving
multiple protein kinases208 (e.g. mitogen-activated protein kinases, MAPK) to facilitate
increases in paracellular permeability and/or degradation of junctional proteins4.
Many DKA cases will present subclinical CE upon admission that may be
exacerbated or resolve during treatment112. The risk of CE has been found to be related to
the severity of the acidosis, metabolic derangement, and usage of bicarbonate as a
treatment108. While insulin administration rates have shown a mild individual correlation to
the risk of CE188, insulin has also been known to upregulate the sodium-hydrogen
exchanger (NHE) activity, allowing water to flow with sodium into cells during DKA
therapy186. In fact, using a NHE inhibitor reduced the cellular swelling during treatment of
insulin and/or alkalization (bicarbonate therapy) in a DKA model158, displaying how during
DKA treatment, the vasogenic CE can become cytotoxic edema. Cerebral autoregulation of
blood flow is also impaired at DKA onset, where metabolic abnormalities such as increased
lactic acid in the brain leads to cerebral vasomotor paralysis156. During correctional fluid
treatment, vasoconstriction caused by hypocapnia66 can be reversed. However, without
cerebral autoregulation, the vessels may vasodilate too far during treatment and increase
cerebral blood flow to facilitate CE, as DKA patients have normal to increased cerebral
blood perfusion rates156. Cerebral autoregulation can then play a role in contributing to the
development of cerebral edema seen in DKA.

1.3.2

« Thrombotic Events (e.g. Stroke) »
Pediatric DKA patients are also at an increased risk for ischemic or hemorrhagic

stroke due to a predisposed prothrombotic state, accounting for 10% of the intracerebral
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complications in DKA58. For example, deep vein thrombosis due to catheter insertion in
pediatric DKA patients are at a 50% increased rate compared to non-diabetic controls70.
Thrombosis occurs when prothrombotic factors overwhelm the antithrombotic properties
(usually found from the vessel wall) and blood begins to stasis due to hypoperfusion.
Prothrombotic factors such as von Willebrand factor (vWF) stored in ECs, megakaryocytes,
and platelets can be released under high shear stress, damage to vessel walls68, or hypoxia
episodes53. While antithrombotic properties of ECs include the tonic production of nitric
oxide (NO) to prevent the release of vWF68, storage of coagulation factors on the
glycocalyx136, and inhibitory regulation of P-selectin needed for platelet adhesion53.
Several systemic inflammatory factors, such as increased PMN degranulation in
DKA can contribute to the prothrombotic state. Increased degranulation of PMNs can be
correlated to coronary thrombotic events19 and leukocytes themselves can release plateletactivating factor (PAF) to facilitate platelet aggregation25. IL-8, a cytokine found to be
increased in DKA138, is also a potent stimulator of PAF on PMNs23. Acute hyperglycemia
has also been correlated to increased platelet aggregation159 while chronic hyperglycemia is
correlated to impaired fibrinolysis (removal of clot)82,105.
Clinically, DKA patients present a perturbed endothelium157 with elevated levels of
vWF, prothrombin fragments, and decreased protein C activity27, which are all factors that
contribute to the prothrombotic state. Even after the DKA episode, T1DM patients continue
to have a prothrombotic state through increased vWF, prothrombin fragments58,
hypercoagulability15, and a sustained increase risk in venous thromboembolism compared
to healthy controls148. Vasoconstriction caused by hypocapnia66, along with dehydration
and increased blood viscosity due to acidemia all contribute to hypercoagulability58.
Consequently, hypercoagulability leads to an increased risk of ischemic brain infarctions
originating from either a stroke, hypoxia, or CE pathogenesis14. The microvasculature is
especially susceptible to disseminated intravascular coagulation where small vessels are
blocked by thrombi, leading to a lack of clotting factors and excessive bleeding in
hemorrhagic conversions from stroke or hypoxia49.
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1.4 « Glycocalyx »
One of the major antithrombotic properties of ECs is the glycocalyx, a mediator in
NO production and release of anti-coagulation factors. All cells possess a glycocalyx, and
the endothelial glycocalyx is known to extend 400-500 nm above the cell surface154. The
glycocalyx is a layer on the surface of cells composed of glycosaminoglycogans (GAGs)
bound to proteoglycans embedded within the cell membrane (Figure 2). These GAGs serve
to regulate vascular homeostasis through mediating signal transductions117. The three most
common GAGs found within the glycocalyx are heparan sulfate (HS), chondroitin sulfate
(CS), and hyaluronic acid (HA)154. HS and CS are both negatively charged sugar moieties
that are bound to various proteoglycans such as syndecans, glypicans, and perlecans154. The
last commonly found GAG, HA, differs from the smaller two GAGS and is a large
hydrophilic sugar polymer (> 1000 kDa) that is capable of self-assembly or binding onto
several hyaladherins such as CD44, receptor for HA mediated motility (RHAMM/CD168),
HA receptor for endocytosis (HARE), and tumor necrosis factor (TNF)-stimulated gene
6154.
The glycocalyx acts as a physical barrier to any molecules larger than 70 kDa,
including cells (e.g. red blood cells). As a result, the endothelial glycocalyx reduces the
effective diameter of the capillary, which contributes to the high resistance found in the
microvasculature154. The GAGs in the glycocalyx also contribute to the anticoagulation
cascade, ROS scavenging, as targets of signal transduction into the cell, as modulators of
the inflammatory response, and the lubrication and cushioning of the joints52. The
glycocalyx is capable of detecting changes in the local environment and adapting, such as
increasing GAG production under high shear stresses or shedding of GAGs within minutes
of TNF-α stimulation12. As an inflammatory mediator, the length of the glycocalyx
normally obscures the binding of platelets and leukocytes through hiding the ligands
(L/P/E-selectins) for adhesion117. Not only are the ligands covered, but the glycocalyx
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constituents act as a steric barrier preventing platelets and leukocytes from adhering45,154.
Therefore, under inflammatory stimulation the glycocalyx is often shed to reveal the
receptors and allow the inflammatory response to proceed60. Studies have shown that under
many inflammatory conditions such as stimulation of TNF-α135, hyperglycemia133,
endotoxemia127, increased oxidized low-density lipoprotein12, and ischemia-reperfusion
injury31 can reduce the thickness of the glycocalyx, implicating the glycocalyx as a
functional step in responding to an inflammatory response from ECs64.
Heparan sulfate chains are mostly made up of disaccharides of a hexuronic acid and
D-glucosamine, with variations of sulfate groups and epimerization of D-glucosamine165.
Heparan sulfate makes up about 50-90% of the chains found in the glycocalyx and its major
role is to detect flow-induced shear responses, modulate the NO response, activation of
coagulation inhibition factors (e.g. antithrombin), and inhibition of cytokines such as
interferon-gamma (IFN-y)154. The ability to detect shear stress and respond to increased
blood flow is facilitated by the glycocalyx. Specifically, it has been found that HS chains
are required to produce the elongated morphological response to shear stress and activate
shear-induced nitric oxide production under flow conditions118. Loss of HS also results in
impaired phosphorylation of endothelial NO implicating a role of the glycocalyx in proper
nitric oxide regulation57. The role of HS when shed also shows a damage-associated
molecule pattern (DAMP), which includes activation of leukocytes and inflammatory
pathways145.
Chondroitin sulfate chains are composed from repeating disaccharides of Dglucuronic acid and N-acetylgalactosamine194. They can be found in a 1:4 ratio to HS but
are known to be abundantly expressed in the central nervous system52. Removal of CS can
increase axonal growth within areas of glial scars by stimulating neurite outgrowth99,52.
Syndecans (SDC-1), are plasma-membrane embedded proteoglycans that attaches both HS
and CS chains and expresses a tightly regulated expression pattern that varies depending on
the chemokine stimulation75. The physical interaction between HS, CS, and SDC-1 can
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therefore lead to connected downstream responses if the shedding of the glycocalyx
targeted the core proteins of HS and CS.
Hyaluronic acid makes up about 40% of the glycocalyx and plays a role in detecting
shear forces, cell motility, and activating proinflammatory or anti-angiogenic pathways63.
Consisting of repeating disaccharides (D-glucuronic acid and N-acetyl-D-glucosamine),
HA is hygroscopic due to hydrogen bounds holding onto water and maintaining the
standalone structure of HA85. The length of HA dictates its main function, with short, low
molecular weight (LMW) HA (< 250 kDa) inducing a proinflammatory phenotype in ECs,
while long, high molecular weight (HMW) HA ( > 1000 kDa) promotes an
immunosuppressive phenotype by inhibiting cell growth and negatively regulating TLR
signaling21. Short HA can also function as a DAMP and directly upregulate IL-8 and MMP2 expression in human endothelial and melanoma cell lines175. HA is also the only part of
the glycocalyx that does not require binding to a proteoglycan when on the cell surface, but
it can bind to CD44, a cell-surface glycoprotein, which is usually involved in cell migration
and wound healing85. Although CD44 is present on platelets and megakaryocytes, allowing
for adherence onto HA94, CD44-negative platelets have been shown to be prothrombotic in
a mouse model, possible suggesting a dual role110. Various cell surface receptors,
glycoproteins, and cell adhesion molecules are covered and overlaid by the glycocalyx,
protecting ECs from activation of coagulation cascades by platelets and inflammatory
cascades by leukocytes154.
Therefore, the constituent changes in GAGs that are associated either with the
production or release of GAGs from the glycocalyx can serve as a marker of endothelial
activation and dysfunction91. Relevant to the pathology of T1DM, a recent study has shown
that the loss of HS at the basement membrane of ß-islets promoted the infiltration of
leukocytes and correlated with the amount of ß-cell loss in an animal T1DM model87. SDC1 levels were also recently found as an independent predictor of mortality among trauma
patients86. In post-mortem patients of stroke, increased HA deposition in the blood vessels,
intracellularly, and nuclei were found in the ECs and inflammatory cells from the regions
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of stroke in the brain2. In endothelial inflammatory diseases such as microalbuminuria,
there are correlations between the reduced size of the glycocalyx and progression of disease
on renal ECs132. Within animal sepsis models, prevention of glycocalyx degradation or
providing GAGs constituents improved the survival of sepsis132. Shedding of the
glycocalyx has been implicated in the inflammatory process in aneurysmal subarachnoid
hemorrhage181, atherosclerosis193, T2DM133, cardiac arrest210, trauma36, and chronic kidney
disease140. It is clear that the glycocalyx is a modulator of the endothelial dysfunction in
multiple diseases.

Figure 1. Schematic representation of the glycocalyx at the brain cerebral
microvasculature.
On the surface of most cells exist a surface layer called the glycocalyx. Major components
include glycosaminoglycans (GAGS; heparan sulfate (HS), hyaluronic acid (HA),
chondroitin sulfate (CS)), and proteoglycans (e.g. syndecan-1 (SDC-1))154. Most
glycoproteins (e.g. CD44, selectins) used in cell-to-cell signaling are covered from the
bloodstream by the dense GAGs. HS and CS are most commonly found bound to SDC-1 or
other proteoglycans, while HA can be found aggregating with itself to form a sticky viscous
layer, or bound to CD44154. The negatively charged GAGs play a role in inflammatory
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signaling, as they can act as binding sites for chemokines, cytokines, and platelet activating
factors, while also attenuating access to endothelial cell adhesion molecules117. The
glycocalyx also serves as a mechanotransducer, affecting nitric oxide production and
changes in vascular tone154. The structural stability of the glycocalyx is independently
contributed by each GAG, as removal of one GAG does not affect the structural integrity of
another GAG. Collectively, the GAGs act as a negative steric barrier to the constituents
found in the open vasculature209.

1.5 « Rationale »
The state of the endothelial glycocalyx in DKA patients has yet to be determined
and how the glycocalyx may contribute to the CED in the context of CE and thrombosis
has not been eluded. Although there is clinical evidence to suggest that the blood of DKA
patients are prothrombotic27,116, a recent study using thromboelastography did not find any
differences in coagulability and instead suggested the injured endothelium as the
contributor to facilitating the prothrombotic state of DKA183. The glycocalyx covers
essential ligands (P-selectins) used by both platelets and PMNs to initiate rolling and
adhesion127,134. The endothelial glycocalyx may then play a role in revealing ligands to
facilitate PMN activation, leading to the release of cytokines and platelet activation and
adhesion. Systemic inflammatory models such as hemorrhagic shock76, sepsis170, and
trauma151 are all in a prothrombotic state26,184 and maintenance of the glycocalyx layer led
to better outcomes indicating that the glycocalyx may be a therapeutic avenue in preventing
thrombosis in DKA. Therefore, the breakdown of the glycocalyx at the cerebral
microvasculature should be investigated to determine if it can facilitate a proinflammatory
and/or prothrombotic state as seen in DKA (Figure 2).
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1.6 « Hypothesis »
I hypothesize that shedding of the glycocalyx from the vascular endothelium would
be increased in the plasma of DKA patients in comparison to age/sex matched insulincontrolled T1DM patients. Any elevations of glycocalyx constituents found in the plasma
of DKA patients will also correlate to DKA severity and removal of the constituent from
human brain cerebral microvasculature in vitro will also result in a prothrombotic and
inflammatory profile.

1.7 « Objectives »


To examine plasma glycocalyx constituents in pediatric DKA and insulin-controlled
T1DM patients and to correlate DKA glycocalyx levels with DKA severity



To examine exogenous removal and addition of glycocalyx constituents and its
effect on inflammatory activation on human brain cerebral microvasculature
endothelial cells (HBMEC)



To examine exogenous addition of glycocalyx constituents and its effect on platelet
adhesion on HBMEC

Figure 2. Schematic flowchart of hypothesis, objectives, and clinical relevance to DKA.

14

2

« Methods »
This study was approved by the Health Sciences Research Ethics Board at Western

University. Patient recruitment took place in our regional tertiary care centre at The
Children's Hospital, London Health Sciences Centre (London, ON, Canada) (Suppl.
Attachment 1).

2.1

« Human Subjects »

Consent for research was procured from the legal guardians of all pediatric patients and
assent was also obtained from T1DM control patients. Pediatric patients considered as
DKA must meet the following biochemical diagnostic criteria: hyperglycemia >11 mmol/l,
bicarbonate <15 mmol/l, and ketonuria. A majority of the DKA cases used in this study
were considered severe (venous pH < 7.1), following these classifications of mild (pH <
7.3) and moderate (pH < 7.2). For controls, insulin controlled T1DM with an HbA1C <
10% and no DKA in the past 3 months were age-sex matched with the study’s DKA
patients. Insulin-controlled T1DM patient data were obtained on routine check-up, while
DKA patients were recruited upon admission to the emergency department. As a result,
certain parameters as seen in Table 1 are missing for CON patients as those parameters are
not routinely measured during visits.

2.2

« Blood Collection and Processing »

Blood from T1DM patients was obtained upon hospital presentation and at the time
of clinically required blood draws. Procedure of collecting and transporting blood has been
standardized according to Translational Research Centre62 (www.translationalresearch.ca;
London, ON). Briefly, citrate-containing tubes (Vacutainers®; BD Biosciences,
Mississauga, ON) were used as an anticoagulant and blood was centrifuged at 1,500 g for
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15 min at 4°C to separate the plasma component. The upper plasma layer was collected into
250 μl aliquots and stored at -80°C before thawed on ice for experimental use. Freeze-thaw
cycles were avoided to prevent any further degradation of glycocalyx components.

2.3

« Glycocalyx Enzyme Linked Immunoassay »

Plasma concentrations of several major constituents of the glycocalyx were
measured via enzyme linked immunosorbent assay (ELISA): SDC-1 (1:2 dilution;
ab46506, Abcam, Cambridge, UK), HS (1:10 dilution; HU8718, Biotang Inc., Lexington,
MA), CS (1:2 or 1:50 dilution; HU8720, Biotang Inc.), HA (1:8 dilution; DHAYL0, R&D
Systems, Minneapolis, MN). Plasma samples were assessed in duplicate. Both DKA and
CON patients’ plasma were used in each assay and dilution factors were adjusted
accordingly to determine actual plasma concentrations. Media of treatment conditions as
explained in the nitric oxide and reactive oxygen assay were also assessed for hyaluronic
acid content in duplicate.

2.4
»

« Human Cerebral Microvascular Endothelial Cells

The primary human brain microvascular ECs (HBMEC; AngioProteomie, Boston,
MA) were used as a model of the brain microvascular endothelium in vitro and as a
representation of where the two main secondary complications (i.e. CE and stroke) of DKA
occurs. HBMEC cultures were maintained in Endothelial Growth Basal Medium (EBM-2;
Clonetics®, Lonza, Basel, Switzerland) supplemented with Clonetics® EGM®-2 MV
SingleQuots kit (Lonza), 0.1% Gentamycin/Amphotericin (GA-1000; Lonza) on fibronectin
(1 g/ml in phosphate buffered saline (PBS); Sigma-Aldrich) coated T-75 plates (Sarstedt,
Nümbrecht, Germany). The cells were kept at 37°C in a humidified atmosphere with 5%
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CO2 and reseeded when the cell monolayer became 70-80% confluent. HBMEC used in the
experiments were limited to passages 7-15 to prevent loss of primary characteristics.

2.5
« Reactive Oxygen Species and Nitric Oxide
Measurement »
HBMEC were first seeded in 4-well plates (ThermoFischer, Waltham, MA) and
grown until confluent. Cells were washed with Hank’s Buffer (HBSS) and allowed to rest
for 1 hr before addition of 200 U/ml of hyaluronidase (HYALase, H3506, Sigma-Aldrich)
or 100 μg/ml of low molecular weight (LMW) HA (GLR001, R&D Systems) for 2 hours at
37°C in a cell culture incubator. HYALase-treated cells were in a HBSS with 0.01% bovine
serum albumin (BSA; A9647, Sigma-Aldrich) solution, while LMW HA-treated cells were
in a HBSS solution. Hydrogen peroxide (H2O2) at 20 M was added to one of the wells as a
positive control for the last 30 min of cell treatment in the reactive oxygen species (ROS)
assay, while of 200 μM of diethylenetriamine NONOate (DETA) was used as a positive
control in the nitric oxide (NO) assay.
To measure the production of ROS content, HBMEC were loaded with 10 uM of
dihydrorhodamine-123 (DHR; a pan-ROS specific fluorochrome) 1 hr into the 2 hr
treatment and covered in the dark. After the treatment(s), cells were then washed with
HBSS 3 times and lysed in a 1% sodium dodecyl sulfate (SDS) in PBS. Lysed cells were
additionally sonicated for 30 seconds (Cole Parmer, Chicago, Illinois) and centrifuged at
10,000 g at 4°C for 5 minutes. Clear supernatants were diluted with Milli-Q water and
placed in a black-wall/clear-bottom 96-well plate (Corning Inc., Corning, NY).
Fluorescence was read at an excitation and emission wavelength of 510 nm and 530 nm,
respectively, on a microplate reader (VICTOR, Perkin Elmer).
To measure endothelial nitric oxide (NO), cells were loaded with 4-amino-5methylamino-2',7'-difluorofluorescein diacetate (DAF-FM; NO-specific flurochrome) at a
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concentration of 10 uM in the same loading conditions as DHR. Supernatants were then
diluted with Milli-Q water in a 10 mm cuvette and read at an excitation of 490 nm and an
emission of 515 nm on a spectroflurophotometer (Shimadzu RF-1501, Shimadzu Corp.).
Protein levels of each sample used in the assays were determined via a
bicinchoninic assay (BCA) kit (Sigma-Aldrich). Fluorescence values of the sample were
then normalized to protein amount and control values. All samples were analyzed in
triplicate readings.

2.6
« Western Blotting of Extracellular Regulated
Kinases (ERK) »
HBMEC were seeded on a 4-well plate (ThermoFischer) and grown to confluency.
Before treatment, cells were washed with HBSS and treated with or without 200 U/ml of
HYALase (H3506, Sigma-Aldrich) in HBSS with 0.01% BSA for 30 min or 2 hours. Cells
were then washed in cold PBS and lysed in a 1% SDS buffer with 1x PhosStop (Roche) and
1x protease inhibitor cocktail (Sigma-Aldrich). Samples were boiled with a SDS sample
buffer containing ß-mercaptoethanol for 5 min. Ten-percent acrylamide gels were used to
separate the proteins and transferred onto a nitrocellulose membrane (162-0177, Bio-Rad,
Hercules, California) overnight at 30 V and 4°C with the Mini Trans-Blot Cell (Bio-Rad).
Membranes were blocked in 2% BSA (Sigma-Aldrich) in Tris-buffered saline (TBS) with
0.05% Tween-20 (TBS-T) for 1hr at room temperature (RT). Primary antibodies used were
phospho-ERK1/2 (p-ERK1/2l 1:1000, ab50011, Abcam), total ERK1/2 (1:1000, ab17942,
Abcam), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:5000, G8795,
Sigma) at their respective dilutions. Primary antibodies were diluted in 5% BSA with TBST and incubated overnight at 4°C. Peroxidase-coupled secondary antibodies used were
rabbit anti-mouse (1:5000, ab97046, Abcam) and goat anti-rabbit IgG (1:5000, A27036,
ThermoFischer). Secondary antibodies were diluted in TBS-T only and incubated for 1 hr
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at RT. Membranes were washed in TBS-T before chemiluminescent substrate was added
and read on a MicroChemi (FroggaBio, North York, Ontario) imager.
Membranes were first probed with p-ERK1/2 before stripped at 60°C for 45 min in
a harsh stripping buffer (2% SDS/0.78% β-mercaptoethanol). Membranes were re-blocked
and then probed with total ERK1/2, imaged, and afterwards probed with the housekeeping
gene, GAPDH. The ratio of phosphorylation in the densitometry values were compared
between the two groups. The ratio between phosphorylation and the housekeeping gene
(GAPDH) were also compared between the two groups.

2.7

« Platelet Adhesion Assay »

Enzymes degrading the glycocalyx may not cleave to the extent seen in
inflammatory signals (i.e. TNF-α33) that cause shedding, possibly underestimating the role
of the glycocalyx, which is why we chose to bolster GAGs in vitro instead of removing the
glycocalyx for this functional assay.
Blood from healthy volunteers that have not taken any anti-histamines or antiinflammatories for the past two weeks was drawn into citrate-containing tubes
(Vacutainers®; BD Biosciences). Blood was centrifuged at 190 g for 15 min at RT with no
break applied. The platelet-rich fraction of the plasma was removed to a new tube and
EDTA was added to a final concentration of 7.7 mM. To collect the platelets, the sample
was centrifuged at 600 g for 10 min at RT. The supernatant was discarded and the pellet
was resuspended in Ca+2 /Mg+2-free HBSS as a wash. Platelets were centrifuged again at
600 g for 10 min at RT and resuspended in Ca+2 /Mg+2-free HBSS. A cell count using a
haemocytometer was done to determine a dilution of 1 x 108 platelets / ml and were
incubated with 0.25 M of CellTracker™ Green CMFDA Dye (ThermoFischer) for 30 min
at RT in the dark. After incubation, platelets were centrifuged at 600 g for 10 min at RT,
resuspended in Ca+2 /Mg+2-free HBSS, and placed in the dark until ready for perfusion.
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HBMEC were grown to confluence in μ-Slide VI0.4 channels (IBIDI, Martinsried,
Germany) in regular EBM-2 supplemented media, while GAG-supplemented media
included EBM-2 supplemented media with the addition of 20 g/ml of HS, 0.12 mg/ml of
HA, and 0.12 mg/ml of CS. Half of the channels received GAG-supplemented media the
night before perfusion, while the rest of the channels received regular EBM-2
supplemented media. All perfusion parameters were performed at 37°C in a temperaturecontrolled chamber, with a shear stress of 0.35 dyn/cm2 and a flow rate of 0.2 ml/min. The
channels were perfused with pH-adjusted EBM-2 only for 1 min to replace the media.
CMFDA-incubated platelets (1 × 107 platelets/ml in EBM-2) were perfused over the cell
monolayer for 5 min and then rinsed with EBM-2 only for 1 minute. Cell monolayers were
then fixed with 3% paraformaldehyde at 37°C for 20 min and washed in 1x PBS at RT. The
number of fluorescent platelets remaining on the cell monolayer was analyzed by
fluorescence microscopy (Zeiss Axiovert 200M; Carl Zeiss, Oberkochen, Germany), using
a digital camera AxioCam MRc (Carl Zeiss) to obtain images. Fluorescent platelets were
counted within each channel in 5 randomly chosen areas and expressed as a % of the
control channel’s fluorescent platelets.

2.8

« Statistical Analysis »

All statistical analyses were done using Graphpad Prism software, with the
threshold of significance being P < 0.05. Data are presented as mean + standard error
(SEM). Data were assessed for normality using the D’Agostino-Pearson test before
applying either a Student’s t-test for parametric data or a Mann-Whitney U-test for
nonparametric data. Correlations were done using non-parametric Spearman correlation.
One-sample T-test (parametric data) or Wilcoxon signed-rank test (non-parametric data)
were done for samples that were normalized to control wells. Data with multiple groups
were compared using the Kruskal-Wallis test and Dunn’s test for multiple comparisons.
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« Results »

3

3.1

« Study Patients »

Plasma was obtained from T1DM pediatric patients, either with acute DKA or in an
insulin-controlled state (CON). The two groups were age and sex matched (n = 20
patients/group). Patients with DKA had significantly higher glycated hemoglobin (HbA1C)
values (P < 0.0001), compared to the T1DM controls, reflecting sustained elevation of
blood glucose over the previous few months (Table 1). DKA patients all had elevated blood
glucose and were in severe metabolic acidosis (mean pH = 7.0, Table 1) compared to ideal
pediatric ranges8. Over half of the DKA patients (n = 12) sampled had their first onset
diagnosis of T1DM via the DKA episode.

Table 1. Patient Clinical Data of Insulin-controlled Type-1 Diabetes Mellitus Patients
(CON) or with Acute Diabetic Ketoacidosis (DKA)
Clinical Data

CON

DKA

11.8 ± 0.7

12.0 ± 0.7

0.808

9:11

9:11

1.00

0.76 ± 0.17

0.27 ± 0.25

0.109

8.3 ± 0.2

11.9 ± 0.5

< 0.0001

pH

N/A

7.0 ± 0.03

HCO3- (mmol/L)

N/A

5.8 ± 0.7

pCO2 (mmHg)

N/A

20.3 ± 1.9

Mean Age (years)
Male : Female Ratio
Body Mass Index Z Scores
HbA1C (%)

P value
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Lactate (mmol/L)

N/A

2.7 ± 0.4

Blood glucose (mmol/L)

N/A

29.3 ± 2.2

Data is presented as mean ± SEM and n = 20 / group, except for HbA1C values for DKA
patients where n = 19. Body mass index (BMI) Z-scores were missing for 4 DKA patients
due to lack of height data and BMI was unable to be calculated. N/A represents data that
was not obtained. A Mann-Whitney or an unpaired t-test was used to determine if there
were any significant differences between CON and DKA, where P < 0.05 was considered
significant.

3.2
« ELISA measurements of plasma glycocalyx
constituents »
Glycocalyx components were measured in the plasma to determine if there was a
specific shedding response in DKA patients compared to insulin-controlled T1DM controls
(CON). There were significant elevations in both HA (8.7-fold increase) (Figure 3A) and
HS (2.4-fold increase) (Figure 3B) in DKA patients (P < 0.001) compared to CON. No
changes were seen between CON and DKA patients in SDC-1 (Figure 3C) and CS plasma
levels (Figure 3D).
Optical density (OD) values that exceeded the kit’s range were replaced with the
maximal value in the kit’s range. Two DKA patients in the HA ELISA assay, and 2
different DKA patients in the SDC-1 assay exceeded the max detectable range and were
replaced. OD values that could not be read were replaced with zero. The SDC-1 levels of 1
insulin-controlled T1DM patient and 1 DKA patient could not be detected and were
replaced with zero.
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A

B

C

D

Figure 3. Plasma Glycocalyx Constituents in Patients with Insulin-controlled Type-1
Diabetes Mellitus (CON) or Acute Diabetic Ketoacidosis (DKA).
A. HA plasma levels in DKA patients were significantly increased compared to CON
patients. B. HS plasma levels in DKA patients were significantly increased compared to
CON patients. C. SDC-1 plasma levels were not significantly different between CON and
DKA patients. D. CS plasma levels were not significantly different between CON and
DKA patients. Data presented for CS are reported in mean pg/ml + SEM.
Optical density (OD) values that exceeded the kit’s range were replaced with the maximal
value in the kit’s range. OD values that could not be read were replaced with zero. A MannWhitney test was used to determine if there were any significant differences between CON
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and DKA, where P < 0.05 was considered significant. Data presented are reported in mean
ng/ml + SEM and n = 20 / group, unless otherwise specified.

3.3
»

« Plasma glycocalyx correlations with DKA severity

Plasma glycocalyx constituents were then compared to several DKA parameters
including blood pH, HbA1C, and bicarbonate (HCO3) levels to determine if there were any
correlations. Only concentration of HA significantly correlated to pH severity, HbA1C
levels, and bicarbonate levels. Lower pH (r = -0.6327, P = 0.0028, n = 20) and HCO3 levels
(r = -0.4901, P = 0.0282, n = 20) correlated to higher levels of HA found in the plasma of
DKA patients (Figure 4A and B), while higher HbA1C (r = 0.4809, P = 0.0371, n = 19)
levels correlated to higher levels of HA found in the plasma of DKA patients (Figure 4C).
A correlation to glycated hemoglobin, implicates HA shedding as related to the prolonged
hyperglycemia period that patients experience before DKA occurs.
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Figure 4. Correlations between plasma glycocalyx constituents and DKA parameters in
DKA patients.
A. Lower pH correlated with higher HA concentrations in DKA patients (P = 0.0028, n =
20). B. Lower HCO3 concentration correlated with higher HA concentrations in DKA
patients (P = 0.0282, n = 20). C. Higher glycated haemoglobin (HbA1c) correlated with
higher HA concentrations in DKA patients (P = 0.0371, n = 19).
A line of best fit was added to show the trend and is only for visual purposes.

3.4
« Endothelial Reactive Oxygen Species (ROS)
Assay »
Bicarbonate derangement in DKA has been shown to be associated with CE
incidence in DKA102 and since HA shedding also correlated to HCO3 levels, HA was either
exogenously removed or added to determine if there were any proinflammatory effects on
HBMEC cells. Although HYALase may not be the major cleaver of HA in DKA (Suppl.
Figure 1), we used HYALase to stimulate the loss of HA on endothelial cells. Other
sheddases (e.g. TNF-α) can activate proinflammatory signalling cascades and bring in
confounding factors.
ROS assays were used to determine if HA induce oxidative stress, as seen in CE of
DKA60. Both LMW HA (P = 0.0078, n = 8) and HYALase (P = 0.002, n = 10) caused a
significant increase in ROS production when compared to unstimulated HBMEC (Figure
5). HYALase produced almost a 2 fold increase while LMW HA produced a 1.3 fold
increase in ROS production, suggesting both the cleaving of HA and the HA fragments can
be implicated in generation of oxidative stress. Interestingly, treating HBMEC with
heparinase (1 U/ml) showed no significant changes in ROS production (data not shown).
The concentration of LMW HA used in this study was chosen based on a range of in vitro
studies seen in literature95,176. HYALase concentrations were chosen based on physiological
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levels in T1DM patients132 and treatment time was based on reduction of the glycocalyx
layer as seen in another study209.
The amount of HA found within the media was also measured via ELISA to
determine that HA existed on the cell monolayers to be shed into the media and that
HYALase was capable of cleaving HA. The amount of HA in the HYALase treatment was
undetectable because the ELISA kit could only detect HA fragments larger than 45 kDa,
indicating that HYALase in our treatment condition was capable of cleaving HA (Suppl.
Figure 2). The ELISA kit has also been used to determine the efficacy of HYALase activity
in another study by measuring the decrease in HA detection147.
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Figure 5. Effect of exogenous LMW HA and HYALase on ROS production in naïve
(unstimulated) HBMEC.
HBMEC were treated with LMW HA, HYALase, or H2O2 (as a positive control) for 2 hrs
and assessed for ROS production with respect to intracellular oxidation of DHR123. Data
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presented are rhodamine fluorescence values expressed as mean + SEM and were
normalized by protein content via BSA assay and unstimulated control HBMEC values.
LMW HA (P = 0.0078, n = 8), HYALase (P = 0.002, n = 10), and H2O2 (P = 0.0078, n = 8)
had significantly higher ROS production as compared to control (dotted line). A nonparametric, Wilcoxon signed-rank test was done to determine any significant differences
compared to control.

3.5

« Endothelial Nitric Oxide Production Assay »

Endothelial NO production was measured to determine if HA could induce
nitrosative stress on naïve HBMEC, similar to the nitrosative stress as seen in CE in
DKA165. Obtained data indicate that HYALase (P = 0.002) treatment caused a significant
decrease in levels of NO compared to unstimulated control or positive control (i.e. DETA)
(Figure 6). HYALase treated HBMEC resulted in almost a 70% decrease of fluorescence,
while there were no significant changes after LMW HA treatment. These findings indicate
that HYALase-dependent removal/cleavage of HA but not the HA fragments per se on an
intact glycocalyx, is responsible for reducing endothelial NO levels.
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Figure 6. Effect of exogenous LMW HA and HYALase on NO production in naive
(unstimulated) HBMEC.
HBMEC were treated with LMW HA, HYALase, or DETA (as a positive control) for 2 hrs
and assessed for NO production with respect to intracellular fluorescence of DAF-FM. Data
presented are DAF-fluorescence values expressed as mean + SEM and were normalized to
protein content via BSA assay and unstimulated control HBMEC values. HYALase-treated
cells had significantly lower levels of NO compared to control (dotted line) (P < 0.0001, n
= 10). A parametric one sample t-test was used to determine any significant differences.

3.6
« Western Blotting of Phospho-ERK1/2 and Total
ERK1/2 »
The mitogen-activated protein kinases (MAPK)-associated signaling (e.g. ERK,
JNK and p38) was explored as a potential signal transducing pathway relevant to the
increased oxidative stress. MAPK/ERK is known as a mediator of inflammatory genes in
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response to stimulation with LMW HA in other cell types (e.g. mesothelial, vascular
endothelial)74,200,81. HBMEC cells were treated with HYALase for either 30 min or 2 hrs
before levels of p-ERK1/2 and total ERK1/2 were quantified via western blot. As cell
signalling changes may occur earlier than the changes seen in the chemical ROS/NO
assays, an earlier time point was also assessed. The obtained results indicate that HYALase
significantly increased levels of p-ERK2 (P < 0.05, Figure 7B) but not p-ERK1 (Figure 7A,
Suppl. Figure 3) at both experimental time points. GAPDH was also probed as a control for
loading and the levels of p-ERK1/2 relative to GAPDH were not significantly different.
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Figure 7. ERK1/2 phosphorylation in HBMEC stimulated with HYALase.
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HBMEC were stimulated with HYALase for 30 min or 2 hrs and assessed for ERK1/2
activation via phosphorylation. A. Representative image of p-ERK1/2, total ERK1/2, and
GAPDH western blots. B. The ratio between the phosphorylation of ERK2 and total ERK2
were calculated and expressed as a percentage. A Kruskal-Wallis test was done to show a
significant increase in density compared to control conditions at 30 min and 2 hrs. Data is
shown as mean % + SEM phosphorylation of ERK2. To correct for multiple comparisons,
Dunn’s test was used to determine significance (*P < 0.05). Comparisons were only made
according to each respective timed control (30 min, n = 5; 2 hrs, n = 7).

3.7

« Platelet Adhesion Assay »

The glycocalyx can inhibit platelet adhesion via steric hindrance49 and masking of
glycoproteins154. Understanding that DKA is of a prothrombotic and proinflammatory
nature, we determined if an intact, augmented glycocalyx would prevent adhesion. HBMEC
were supplemented with GAGs overnight before naïve, unstimulated platelets were
perfused over. All three major GAG components were supplemented as there were
significant increases in HS and HA shedding in DKA plasma and multiple studies have
used CS in complement with the other GAGs to therapeutically restore the glycocalyx77,170.
When HBMEC were grown in supplemented GAG media, there was a significant decrease
(P < 0.05, n = 6) in platelet adhesion when compared to control indicating that platelet
adhesion (Figure 8) is inhibited by an optimal glycocalyx layer.
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Figure 8. Platelet adhesion on HBMEC monolayers grown in normal EBM-2+ (CON) or
EBM-2+ with GAGs supplementation (+HA/HS/CS).
Data is presented as a ratio to the number of platelets found compared to control + SEM.
HBMEC monolayers that had media supplemented with GAGs showed a decrease in
platelet adhesion (P < 0.05, n = 6). A non-parametric, Wilcoxon signed-rank test was used
to determine if there was any difference compared to control.

3.8

« Negative Experimental Data »

There are 4 additional supplemental figures that returned negative data, as we
experimentally looked at several functional assays under the treatment of exogenously
addition/removal of GAGs: integrity (Suppl. Figure 4) and permeability of HBMEC assays
(Suppl. Figure 5) and leukocyte adhesion assays (Suppl. Figure 6-7).
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4

« Discussion »
Experiments were conducted to quantify glycocalyx constituents in DKA plasma

and to correlate glycocalyx levels to DKA severity. Data suggests that DKA patients are
undergoing increased glycocalyx shedding compared to their insulin-controlled T1DM
counterparts and cleavage of the glycocalyx can lead to an activated and prothrombotic
state on the endothelial cells characterized by ROS production and depressed basal NO.
Our findings of decreased platelet adhesion on an optimal glycocalyx agree with current
literature that a loss of glycocalyx can lead to an increase risk of microvascular dysfunction
and thrombosis as seen in DKA.

4.1

« Glycocalyx Status in DKA »

We looked to determine the role of GAGs in vascular dysfunction in DKA as the
glycocalyx have been shown to be a modulator in various inflammatory diseases and
involved in many roles of the endothelium. We found an 8.7-fold increase in HA and a 2.4fold increase in HS (Figure 3) under DKA conditions compared to T1DM. Inflammatory
diseases that similarly have increased HA and/or HS shedding include trauma151, diabetic
angiopathy118, ischemic stroke2 and sepsis131; all indicating that the loss of HA and HS are
involved with the pathogenesis of vascular deterioration. T1DM patients have higher levels
of HA and HYALase compared to healthy non-diabetic controls: implicating that DKA
patients are undergoing a greater level of HA shedding134. Increased HA shedding can be
attributed to the inflammatory and hyperglycemic state of DKA, where healthy controls
when given a hyperglycemia insult, plasma HA levels were increased along with a reduced
glycocalyx volume135.
The increase of HS in DKA compared to T1DM may not have as great of a fold
change as HA because T1DM patients may already have altered sulfation of HS as seen in
human biopsies92 samples and low HS levels due to increased excretion106 compared to
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non-diabetic patients. Although levels of SDC-1 were not significantly elevated in DKA
patients, SDC-1 is a protein adhered into the cell through a transmembrane domain191 and
has been known to be increased in plasma under conditions of diabetic nephropathy115,172,92,
where the basement membranes of the renal tubules are also undergoing HS changes.
Noting that SDC-1 is a marker of trauma88 and severe vascular damage (e.g.
hemorrhage181) SDC-1 shedding may be more of an indicator of severe endothelial
membrane damage or protease activity, and is not seen in DKA patients unless secondary
complications like clinical CE occurs.

4.1.1

« Increased HA in DKA Plasma
One of the primary roles of free HA is to be a mediator of inflammation more so

than procoagulation. Addition of medium molecular weight (MMW) HA (250-1000 kDa)
onto unstimulated endothelium or PMNs3 provides little to no effect, but the results
dramatically differ when low (10-250 kDa) or short (< 10 kDa) HA are added, especially to
activated cells. This is not surprising, as HA turnover produces medium-sized HA
fragments and is fairly constitutive with 1/3 of HA being replaced daily and around 10-100
mg of HA entering the blood per day37,175. Short HA can act as a DAMP as it is usually
only produced in acidic endosomes162,72. HA acting as a DAMP can be found to activate
many inflammatory pathways such as induction of chemokine and MMP genes in mouse
macrophages168, MMP-9 and IL-8 mRNA upregulation in tumor cells112, and rapid tyrosine
phosphorylation and proliferation in endothelial cells198.
High molecular weight ( > 1000 kDa, HMW) HA has been recognized as essential
for anti-inflammatory142, antiangiogenic and immunosuppressive properties, but can also
vary depending on the cell type it acts on197. Pretreatment with HMW HA can be
protective137 to inflammation and apoptosis as the molecular fractions of HA usually shifts
to decreased amounts of HMW HA to increased MMW or LMW HA as seen in
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inflammatory models of asphyxia139, lung inflammation in fibrosis176, skin wounds46, and
knee osteoarthritis10.
The effect of free HA also depends on context and size-specific conditions. As the
ELISA kit limits the detectable length of HA to be no shorter than 35 kDa, it is unclear
whether the effect of free HA is of a proinflammatory or anti-inflammatory nature.
However, the increased amounts of HA found in DKA plasma is most likely part of the
inflammatory response. HA shedding caused by inflammatory disorders such as acute lung
injury have been known to be proinflammatory and of a LMW nature84. Other
inflammatory responses such as cigarette smoke exposure18,103, atherosclerosis lesions17,
and aortic catheter injuries26, have all shown an increase in LMW HA after stimulation.
LMW HA can bind via TLR-2 in endothelial cells to stimulate a lower
proinflammatory response (e.g. upregulating E-selectin and IL-8) in comparison to
canonical inflammatory cytokines such as TNF-a150, indicating that LMW HA acts as a
primer on ECs for further activation. LMW HA can induce IL-8 transcription and
production via TLR-4 after 8 hours on dermal endothelial cells175. Another aspect affected
by the plasma are the immune cells, including macrophages, and PMNs. Human
macrophages stimulated with LMW HA have been shown to have increased MMP-9
activity, while HMW HA downregulated MMP-9 activity17. The activity of MMP-9 from
PMNs and endothelial cells can also be induced by LMW HA150. Potentiating the effect of
MMPs would further the endothelial dysfunction, as HMW HA binds tightly to CD44201,
which if broken, could increase MMP-9 docking to endothelial CD44. However, LMW HA
may also be necessary for proper inflammatory responses, as it can induce neutrophil
apoptosis in protection from an inflammatory lung injury response107, once again showing
the context specificity manner of HA.
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4.1.2

« Increased HS in DKA Plasma
HS has a duality nature in propagating inflammation. Intact HS on the glycocalyx is

used to slow neutrophil and monocyte rolling velocity via L-selectin64,165, while free HS act
as a chemotactic gradient towards the damaged area164, implicating HS as a crucial player in
the endothelial inflammatory processes that can facilitate CE. Free HS could bind up
cytokines such as IL-2182, IFN-y76, IL-10160, or enhance its activity such as preventing its
degradation in IL-6128 or have a synergistic effect on cell proliferation with IL-5109.
Heparinase-cleaved fragments of HS in human mononuclear cells can induce cytokine
release (IL-1B, IL-6, IL-8, IL-10, and TNFα) via TLR-4 pathway67. Increases in free HS
detected in the plasma can then contribute to the inflammatory profile of DKA patients
where there is a significant increase in IL-6, CXCL-1, and IL-8 levels138. In fact, free HS
can bind to IL-8 to increase neutrophil cystolic free Ca+2 and chemotaxis by 4-fold196.
Increases in cytokine activity, or leukocyte activation on the endothelium would
inevitably activate platelet adhesion through release of vWF as P-selectin is revealed on the
surface of ECs149. The duality exists too for platelet adhesion, as IL-8 upregulates PAF,
while TNF-α promotes an anti-thrombotic state in the vasculature via increased NO24. HS is
known to bind antithrombin to inhibit the coagulation cascade, however the knock-out of a
sulfation enzyme needed for HS in mice did not reflect a prothrombotic state, indicating
that another GAG (such as CS) may be responsible in compensating for the antithrombin
binding197 when HS is not available.

4.1.3

« Source of Glycocalyx Shedding »
Glycocalyx shedding has primarily two consequences, the removal of glycocalyx

from the source and the free glycocalyx constituents within the blood. The increase in
shedding found in DKA could be due to changes of degradation or synthesis of HA. HA
synthesis enzymes (HAS) are usually found to produce HMW to MMW HA, while only
HAS-3 secretes HA of a lower weight (100 kDa – 1000 kDa)175. Some cytokines like TNF-
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α can enhance HA surface levels without changes in mRNA for HAS or HYALase123,
while other cytokines (e.g. IL-1B, TGFB) can alter transcription of HAS163. However the
more proinflammatory lengths of HA are not seen to be naturally synthesized, but created
through degradation124. The two degradation pathways of HA involve HYALase-1 or
HYALase-2 but both are CD44 dependent124. HYALase-1 is the HYALase primarily found
in the plasma42, but its activity is only optimal at a pH range of 4.0 and found intracellularly
in lysosomes to cleave HA down to tetrasaccharides72,194. HYALase-1 is unique in that its
activity hydrolyzes CS faster than HA, showing duality as a lysosomal enzyme206. The
ability of HYALase-1 to cleave HA to tetrasaccharides at low pH intracellularly indicates
why LMW HA acts as a DAMP. HYALase-2 is linked to the cell membrane and degrades
HA to 20 kDA fragments194, which can stimulate inflammatory cytokine production72. It
has an optimal pH at 6-7 and HYALase-2’s degrading activity is potentiated when detected
with co-expression of CD4472. Knowing that the plasma pH of DKA is fairly acidic (Table
1), the activity of HYALase-2 is optimized in severe DKA. Although HYALase was not
found to be significantly increased in DKA plasma (Suppl. Figure 1), a trend exists and
HYALase may not be free floating in the plasma, but bound on to the cell surface acting on
the glycocalyx instead, like the mechanism of HYALase-2.
The loss of the glycocalyx can lead to increased platelet adhesion12 and platelets are
a rich source of HYALase-2 and heparinase. Platelet-origin HYALase-2 could cleave HA
off endothelial cells and those fragments subsequently act as an inflammatory signal to
monocytes45. However, there are serum HYALase inhibitors (ascorbic acid80, inter-alphainhibitor (IαI) derived122, HS compounds63) that need to be accounted for and how they
interact with the plasma HYALase-1 and cell-surface bound HYALase-2 remains unclear.
HYALase are not the only pathways of producing LMW HA, as ROS activity can
fractionate HA to LMW HA54 and increase HYALase-2 activity in epithelial cells via P38
MAPK125. Other proteinases commonly found at inflammatory sites such as cathepsin B,
elastase, and proteinase-3 all increase HA shedding, but whether that is due to degradation
of HA or the HA-bound receptor CD44 remains unclear12. ROS production via neutrophil
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degranulation of elastase and MMP8/9 is implied in DKA202, and thus, the increases in HA
shedding can be accounted for and as well participate in facilitating inflammation through
free HA fragments.

4.1.4

« Consequences of Glycocalyx Shedding »
Although the actions of LMW HA may be proinflammatory, the removal of HA on

endothelial cells may actually be protective. Studies have shown that removal of HA on
activated endothelium have resulted in decreased CD44/HA-mediated rolling of
lymphocytes88 and adhesion in neutrophils129. There are other methods for leukocytes to
bind to the endothelium through integrins and HA is not required for the adhesion in
neutrophils129. There may be an additional insult required in order for the removal of HA on
the endothelium to be no longer protective, as HYALase-treated rats under a model of
asphyxia led to worse outcomes210, or that an accumulation of LMW HA (such as in the
microvasculature) is more likely to potentiate proinflammatory effects as cleaved HA is
cleared away after HYALase-treatment. A majority of the studies done with LMW HA
have also used long incubation periods150 indicating that cells may require persistent or
elevated levels of LMW HA to be stimulatory.
The role of HA shedding is likely to be a consequence of prolonged hyperglycemia
and an inflamed circulation. In DKA, the majority of the HA appears to be shed from the
endothelium, as the levels of HA are a representative marker of endothelial damage since it
correlates to pH severity, extent of hyperglycemia, and bicarbonate imbalance in DKA
patients (Figure 4). Although there may be an increased production of HA123, there is much
more evidence that under inflammatory conditions, an increase in GAGs in the media or
circulation reflects a decrease in glycocalyx thickness in the vasculature
endothelium12,20,21,126,174. The effects of increased plasma HA could mean a degradation of
protective HMW HA, an increase of LMW HA acting as mostly proinflammatory signals,
or increased shedding of the endothelium as a protective response.
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4.2

« Microvasculature Dysfunction »

Next, we looked to see if the endothelial microvascualture would have any
dysfunction after HA shedding by examining the chemical aspect of endothelial activation
and prothrombotic conditions.

4.2.1

« Increased ROS after HA Cleavage »
Both LMW HA and HYALase resulted in an increase in intracellular ROS,

indicating that it is most likely the increase in free LMW HA that is causing the HBMEC to
increase in ROS production in comparison to control rather than the cleavage of HA from
HBMEC (Figure 5). LMW HA has been shown to stimulate ROS production via NADPH
oxidases in vascular smooth muscle189 and macrophages via CD4471 in vitro. Shedding of
HA could then exacerbate the increased ROS production via NADPH oxidases as cells
undergoing hyperglycemia, similarly have overactivation of NADPH oxidases83 dependent
on the protein kinase C pathway199. Exogenous ROS on platelet activity appears to be dosedependent and relies on superoxides reacting with NO, limiting the NO bioavailability to
increase platelet aggregation97.

4.2.2

« Decreased NO after HA Cleavage »
Next, we looked at one of the major inhibitors of platelet activation – NO. The

reduction of NO seen in only HYALase treated HBMEC indicates that the first step of
removing HA from endothelial cells is necessary to cause a decrease in NO, rather than
only the cleaved products of HA (Figure 6). Under healthy endothelial cells, circulating HA
would not dysregulate NO production. Due to the short treatment time, the changes in NO
are most likely due to an endothelial NO synthase (eNOS) as it regulates short bursts of NO
in a calcium-dependent manner121,199. In endothelial cells, when HA is removed, the
association of CD44, inositol triphosphate receptors (calcium channels), ankyrin
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(cytoskeleton protein), and caveolin-1167 (CAV-1) falls apart. CAV-1 and heat shock
protein-90 usually remain bound to eNOS59 as an inhibitor in unstimulated cells207. Without
HA stabilizing the congregation of calcium channels and CAV-1 via CD44, eNOS would
be further inhibited and basal NO production would be decreased. In vivo naturally
expressed HA in renal endothelial cells show clustering of CD44, and if inhibited, shows
reduced clustering207 impacting the possibility of CD44 being grouped into caveolae.
Increased ROS as seen above, can reduce bioavailability of NO by creating peoxynitrite,
which is another molecule that can disrupt endothelial caveolae grouping with eNOS28.
In the vasculature of diabetic patients, the endothelium has been known to have
dysfunctional NO productivity resulting in an increase of superoxide availability and
NADPH protein expression41,83. Increased C-reactive protein (CRP) circulating in diabetic
patients can also suppress basal NO release via decreased mRNA availability190. CRP is
commonly found to be increased in T1DM patients43 and associated to systemic
inflammatory response syndrome in DKA98. NO is essential in dynamic endothelial
responses as it acts as an anti-inflammatory regulator by mitigating VCAM-1 expression
after cytokine stimulation on endothelial cells44, reduce superoxide production40, and
adhesion on leukocytes61, and basal inhibition of platelet activation161. Peroxynitrite is
catalyzed faster than hydrogen peroxide from superoxides28 and in low concentrations can
inactivate the antithrombotic prostacyclin synthase213. Depressed NO has also been found
in other inflammatory diseases such as atherosclerosis137, myocardial ischemia and
perfusion114, and hypercholesterolemia104, giving a strong indication that when the
endothelium is under an inflammatory response, NO production is dysregulated.
NO is important in cerebral blood flow regulation. Cleaving of HS57 or HA141
blocked shear induced NO production, essential in adjusting vascular tone to changes in
cerebral blood pressure179. HA can act as a mechanotransducer by binding to and clustering
the CD44 receptor in caveolae to phosphorylate eNOS, leading to NO production in
response to shear stress173. The loss of HA and HS can then contribute to the impaired
autoregulation found in DKA patients113. NO has also been shown to ameliorate the
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impaired CO2 vasoreactivity in patients with endothelial dysfunction (DM or
hypertension)102, implicating the importance of NO production in the dynamic acidic
environment during DKA onset. The lack of HA to produce a counter NO vasodilation to
the vasoconstrictive hypocapnia119,156 in DKA could lead to increased fluid influx and risk
of thrombosis. Shedding of the glycocalyx would then be a contributor to the NO
dysfunction found in the endothelium of DKA patients.
Under hyperglycemic conditions, oxidative stress increases while NO
bioavailability is decreased in endothelial cells41,87. DKA patients with fatal CE have been
found to have increased oxidative and nitrosative stress markers within the brain78,79.
Increased cleavage of HA from the endothelium or circulating LMW HA in the plasma of
DKA can facilitate and participate in the increased oxidative state of the brain endothelium,
while shedding of the HA from the endothelium would result in lowered NO production,
possibly affecting cerebral autoregulation and playing a major role in the prothrombotic
state of DKA.

4.2.3

« Increased ERK2 phosphorylation under HYALase-treated
HBMEC »
To narrow down the effect of elevated shedding of HA seen in the increase in ROS

or decrease in NO, we looked into ERK cascades to see if it was involved in facilitating the
responses. There was a strong increase in ERK2 phosphorylation compared to control
(Figure 7B) when HBMEC was stimulated with HYALase for 30 min or 2 hr. Similarly,
ERK phosphorylation increased due to the addition of HA or LMW HA in human lung
endothelial cells111. However, another study using bovine endothelial cells showed only
increased ERK1 phosphorylation168 but the fragments used were of fairly small
oligosaccharides and HA has been known to be cell-type specific142. Oligosaccharides of
HA have also been shown to increase ERK1/2 phosphorylation dependent on CD44
transiently within 5 minutes in placental endothelial cells195.
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Within our model, it is hard to distinguish between which size of HA is acting on
the cells as HA is a repeating disaccharide, but it appears that LMW HA is the likely
instigator of ERK phosphorylation as seen in other studies. HA fragments binding onto
TLR-4 can facilitate cytokine production as seen in previous studies175,176. The breakdown
of HMW-HA could also be a facilitator of inflammation, as HMW-HA is needed to inhibit
stimulated TLR-4 signaling via decreasing ERK1/2 phosphorylation205. As both HYALase
(Figure 7) and exogenous HA74,111,168 in other cells can activate ERK phosphorylation in
endothelial cells, this pathway seems to be involved with ROS production rather than NO
inhibition. In endothelial cells, ROS have been known to increase permeability in the brain
microvasculature by downregulating tight junctions via ERK phosphorylation56. The ROS
produced by HYALase could be increasing ERK phosphorylation instead of direct
interaction between HA and ERK phosphorylation. Shedding of HA can then facilitate
increased ROS to promote ERK phosphorylation, increased permeability at the BBB in
DKA, and lead to CED.

4.3
« Inhibition of Platelet Adhesion via Enhanced
Glycocalyx »
Lastly, we wanted to establish the relationship between platelet adhesion and
integrity of the glycocalyx on endothelial cells. DKA is known to be a prothrombitic state27,
indicating that increased platelet aggregation can release enzymes to further degrade the
glycocalyx and facilitate cerebrovascular complications. Increased platelet aggregation in
DKA patients can be detrimental especially in young pediatric patients where there is a
50% increased rate of clinical deep venous thrombosis when inserting a central venous
catheter58. Acute hyperglycemia studies have also shown that a loss of endothelial
glycocalyx correlates to increased platelet adhesion133, while some studies point to the lack
of NO bioavailability as a contributor to platelet aggregation65,159. Although clinically, there
have been reports of increased procoagulation factors in DKA patients58, a recent report has

43

suggested it is not the platelets that are activated, but instead the authors suggest an
endothelial nature to the prothrombotic state of DKA183.
The glycocalyx is known to regulate coagulation cascades, as HS can inactivate
thrombin via anti-thrombin III178 or bind to tissue factor pathway inhibitor154 to prevent
coagulation. The negative charge of the glycocalyx can also repel platelets from
approaching the endothelial cells6 and as a mechanotransducer affecting NO bioavailability,
we looked to see if supplementing an in vitro model of the microvasculature with GAGs
would bolster the glycocalyx to reduce platelet adhesion. Our results show that when
supplementing the media with GAGs, platelet adhesion is reduced (Figure 8) when
compared to cell monolayers grown under normal media. Although our ELISA results
show that our model possess HA (Suppl. Figure 2), the glycocalyx layer may not be as
developed as in vivo models. Cleaving of the glycocalyx on the cell monolayer may result
in little to no change in adhesion or rolling as seen in experiments with PMN
rolling/adhesion and HYALase on naïve HBMEC (Suppl. Figure 6-7), similar to heparinase
which showed no changes in white blood cell adhesion after infusion127. Destabilization of
the glycocalyx may result in removal of selectins required for rolling and adhesion,
implicating that shedding may be a natural response to inflammation127. In support of that,
removal of HA on rat fibrosarcoma cells have also shown to diminish platelet adhesion94.
However, further degradation may overwhelm the protective effect as knockouts of CD44
(that binds to HA) had the opposing effect110.
Our results show a decrease in platelet adhesion after GAG supplementation in
HBMEC. This is consistent with the literature, where pretreatment with Sevoflurane, a
vapour anesthetic and protector of glycocalyx degradation, lead to reduced platelet
adhesion in ischemic-reperfusion in guinea pig hearts32. When glycocalyx is removed via
oxidative stress in vivo, platelet adhesion increased and diminished as the oxidative stress
was inhibited192. Overall, an intact glycocalyx is associated with decreased platelet
adhesion. The glycocalyx is important in maintaining NO bioavailability as described
above, and in particular of endothelial cells, NO tonically inhibits platelet activation in
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healthy human volunteers161. Consequentially, the glycocalyx and NO availability have
been essential to creating biomaterial for medical devices to reduce platelet adhesion when
implanted in the vasculature166. The depression of endothelial NO by HYALase-treated
HBMEC (Figure 6) also implicate the glycocalyx’s contribution to the prothrombotic state
of DKA.

4.4
4.4.1

« Clinical Significance and Limitations »
« Clinical Significance »

We have elucidated the glycocalyx status in DKA patients, with findings of
increased shedding of HA and HS compared to their insulin-controlled counterparts. Our
experiments have also shown that shedding of HA can contribute to endothelial dysfunction
via increase in ROS, and a prothrombotic endothelial state via depressed NO production.
We have demonstrated that perturbed glycocalyx can contribute to increased platelet
adhesion, leading to increased susceptibility for prothrombotic events in DKA patients, and
opening up the glycocalyx as a possible therapeutic avenue (Figure 9).

4.4.2

« Limitations »
Several limitations are to be noted. There is a trend of higher enzyme activity of

HYALase in the plasma of DKA compared to insulin-controlled T1DM patients (Suppl.
Figure 1), but despite the lack of significance, according to the literature, we would expect
a higher in vivo activity as HYALase enzymes have an optimal pH of 7 or lower73.
Therefore in DKA patients, HYALase activity should be much higher during acidosis and
at sites of PMN degranulation90. Not all the HYALase enzymes may be free floating in the
plasma, as they may be docked to the endothelial wall and cleaving HA before being
endocytosed into the cell as most HYALase enzymes are72. The Morgon-Elson reaction
assay39 used to determine HYALase requires that both plasma samples be in a buffer of pH
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4.0, eliminating the natural pH difference between the two conditions, and the HYALase
enzymes may be inhibited through HS, or a circulating inhibitor122 that is part of the IαI
family in the plasma. The HYALase used in our in vitro model was of a mammalian origin,
but not human. Bovine HYALase could have also cleaved HA in different MW fragment
ratios compared to human HYALase, which could represent different contexts of the HA
environment presented to the cells, and lead to different intracellular responses143.
Our BBB model is also of a static nature, therefore the effect of altered NO
production may be minimized when shear flow is not accounted for and the status of the
glycocalyx is unknown. Although a recent paper has shown that a cellular in vitro model is
capable of developing a full glycocalyx50, while others have shown an insufficient layer of
glycocalyx via different techniques33. Our model lacks other factors when accounting for
DKA, such as the hyperglycemia and ketoacidosis.

4.4.3

« Future Directions »
One of the future directions is to look for the main mechanism of shedding, whether

it is mainly attributed to the prolonged hyperglycemia, an enzyme, or the increased
activation of PMNs, should be explored as a therapeutic direction. Future studies are
required to look at the specific size and context the HA is being shed and consequently, the
downstream effect to better predict its role in inflammation and susceptibility to secondary
complications, like CE. The damaged glycocalyx in DKA can be safely repaired through IV
supplementation of GAGs and should be targeted as a potential therapeutic intervention,
similarly in septic shock170. Platelet studies should be taken to an in vivo DKA model and
the glycocalyx should be reconstituted with GAG supplementation to measure the effect on
thrombotic events and platelet adhesion. There have been studies on antithrombin
preventing glycocalyx degradation30 as a therapeutic treatment, however, one study points
to antithrombin’s inhibitory effects were on proteases as the mechanism of action instead of
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platelets themselves34. Ameliorating the glycocalyx may be the other main mechanism to
reduce platelet adhesion and the prothrombotic tendency of DKA patients.

4.5

« In Conclusion »

Overall, shedding of the glycocalyx in DKA has been shown to be specific in HA
and HS, however it is only HA that correlated to severity of DKA. HS and HA can
potentiate the major circulating cytokines (IL-8/IL-6) in DKA patients to exacerbate the
damage in the endothelium. HA appears to be representative of the endothelium health, as it
acts as a modulator to the inflammatory response via immune and endothelial molecules.
Specifically in HBMEC cells, removal of HA or exogenous addition of LMW HA can
stimulate ROS production leading to endothelial dysfunction. Only the removal of HA from
HBMEC would suppress NO production and combined with the ROS production status, it
points to a prothrombotic response from the endothelium (Figure 9). Platelet adhesion is
also decreased when cells are grown with a GAG supplementation, implicating the role the
protective role of a glycocalyx to prevent thrombotic events. Overall, the shedding of the
glycocalyx in DKA patients is an indicator of endothelial health and patients with increased
shedding should be observed closely for susceptibilities to dysfunctional endothelial
complications, such as thrombosis and CE.

47

Figure 9. Proposed mechanism of microvascular dysfunction leading to CE and thrombosis
in DKA patients as adapted from Woo (2015)204.
Prolonged hyperglycemia and ketoacidosis increases circulating proinflammatory
cytokines and induce glycocalyx shedding. The proinflammatory state in DKA can recruit
PMNs to the inflamed endothelial cell surface, which may have also lost its glycocalyx,
leading to easier access to the endothelial cells attenuating microvascular leak through
degranulation of proteases. Both degranulated proteases and glycocalyx fragments can then
potentiate circulating cytokines in a positive feedback loop to recruit more immune cells to
the microvasculature. Meanwhile, loss of the glycocalyx increases ROS production and
decreases endothelial NO production, a potent inhibitor of coagulation. Decreased NO
bioavailability can prime the endothelial cells into a prothrombotic state, leading to
increased risk of thrombosis in DKA patients. We propose that microvascular dysfunction
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complications, such as CE or thrombosis found in DKA, can be attributed to the breakdown
of the BBB via protease activity, increased ROS production, decreased basal coagulation
inhibition via depressed NO, and shedding of the glycocalyx to expose the ECs to immune
cells.
Compared to the dysfunction found in DKA, healthy endothelium have an intact
glycocalyx that covers over adhesion molecules and glycoproteins needed for rolling and
adhesion of platelets and PMNs, provides sufficient NO bioavailability, and acts as a
negative steric barrier, separating entities away from the endothelial cell.

49

References
1.
2.
3.
4.

5.

6.
7.
8.
9.
10.
11.

12.
13.
14.
15.

16.
17.
18.

Abbott, N. J. et al. In Vitro models of CNS Barriers. Drug Delivery to the Brain. 10,
(2014).
Al’Qteishat, A. et al. Changes in hyaluronan production and metabolism following
ischaemic stroke in man. Brain 129, 2158–2176 (2006).
Alam, C. A. S. et al. The inhibition of neutrophil-endothelial cell adhesion by
hyaluronan independent of CD44. Inflammopharmacology 12, 535–550 (2005).
Alexander, J. S. & Elrod, J. W. Extracellular matrix, junctional integrity and matrix
metalloproteinase interactions in endothelial permeability regulation*. J. Anat. 200,
561–574 (2002).
Allen, C. L. & Bayraktutan, U. Antioxidants attenuate hyperglycaemia-mediated
brain endothelial cell dysfunction and blood-brain barrier hyperpermeability.
Diabetes, Obes. Metab. 11, 480–490 (2009).
Alphonsus, C. S. & Rodseth, R. N. The endothelial glycocalyx: a review of the
vascular barrier. Anaesthesia 69, 777–784 (2014).
Association, C. D. 2. Classification and Diagnosis of Diabetes. Diabetes Care 40,
S11–S24 (2017).
Association, C. D. 12. Children and Adolescents: Standards of Medical Care in
Diabetes—2018. Diabetes Care 41, S126–S136 (2018).
Association, C. D. Diabetes: Clinical Practice Guidelines. Can. J. Diabetes 37, 212
(2013).
Band, P. A. et al. Hyaluronan molecular weight distribution is associated with the
risk of knee osteoarthritis progression. Osteoarthr. Cartil. 23, 70–76 (2015).
Battelino, T. et al. The use and efficacy of continuous glucose monitoring in type 1
diabetes treated with insulin pump therapy: a randomised controlled trial.
Diabetologia 55, 3155–3162 (2012).
Becker, B. F. et al. Degradation of the endothelial glycocalyx in clinical settings:
Searching for the sheddases. Br. J. Clin. Pharmacol. 80, 389–402 (2015).
Bevilacqua, M. P. et al. Endothelial-leukocyte adhesion molecules in human
disease. Annu Rev Med 45, 361–378 (1994).
Bialo, S. R., Agrawal, S., Boney, C. M. & Quintos, J. B. Rare complications of
pediatric diabetic ketoacidosis. World J. Diabetes 6, 167–74 (2015).
Binay, C. et al. Evaluation of Coagulation Profile in Children with Type 1 Diabetes
Mellitus Using Rotational Thromboelastometry. Indian J. Hematol. Blood Transfus.
33, 574–580 (2017).
Björk, E. et al. Glucose regulation of the autoantigen GAD65 in human pancreatic
islets. J. Clin. Endocrinol. Metab. 75, 1574–1576 (1992).
Bot, P. T. et al. Hyaluronic acid metabolism is increased in unstable plaques. Eur. J.
Clin. Invest. 40, 818–827 (2010).
Bracke, K. R. et al. Enhanced deposition of low-molecular-weight hyaluronan in
lungs of cigarette smoke - Exposed mice. Am. J. Respir. Cell Mol. Biol. 42, 753–
761 (2010).

50

19.
20.

21.

22.
23.
24.
25.

26.
27.
28.

29.

30.
31.
32.

33.

34.

35.
36.

Brennan, M.-L. et al. Prognostic value of myeloperoxidase in patients with chest
pain. N. Engl. J. Med. 349, 1595–604 (2003).
Broekhuizen, L. N. et al. Effect of sulodexide on endothelial glycocalyx and
vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53,
2646–2655 (2010).
Bruegger, D. et al. Atrial natriuretic peptide induces shedding of endothelial
glycocalyx in coronary vascular bed of guinea pig hearts. Am. J. Physiol. 1993–
1999 (2005). doi:10.1152/ajpheart.00218.2005.
Buhren, B. A. et al. Hyaluronidase: from clinical applications to molecular and
cellular mechanisms. Eur. J. Med. Res. 21, 5 (2016).
Bussolino, F. et al. Synthesis of platelet-activating factor by polymorphonuclear
neutrophils stimulated with interleukin-8. J. Biol. Chem. 267, 14598–603 (1992).
Cambien, B. et al. Antithrombotic activity of TNF-α. J. Clin. Invest. 112, 1589–
1596 (2003).
Camussi, G. et al. Release of platelet-activating factor (PAF) and histamine. II. The
cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and
basophils. Immunology 42, 191–9 (1981).
Cap, A. & Hunt, B. J. The pathogenesis of traumatic coagulopathy. Anaesthesia 70,
96-e34 (2015).
Carl, G. F. et al. Diabetic ketoacidosis promotes a prothrombotic state. Endocr. Res.
29, 73–82 (2003).
Cassuto, J. et al. Peroxynitrite Disrupts Endothelial Caveolae Leading to eNOS
Uncoupling and Diminished Flow-Mediated Dilation in Coronary Arterioles of
Diabetic Patients. Diabetes 63, 1381–1393 (2014).
Chajara, A. et al. The fibroproliferative response of arterial smooth muscle cells to
balloon catheter injury is associated with increased hyaluronidase production and
hyaluronan degradation. Atherosclerosis 157, 293–300 (2001).
Chappell, D. et al. Antithrombin reduces shedding of the endothelial glycocalyx
following ischaemia/reperfusion. Cardiovasc. Res. 83, 388–396 (2009).
Chappell, D. et al. Protection of glycocalyx decreases platelet adhesion after
ischaemia/reperfusion: an animal study. Eur. J. Anaesthesiol. 31, 474–81 (2014).
Chappell, D. et al. Sevoflurane Reduces Leukocyte and Platelet Adhesion after
Ischemia-Reperfusion by Protecting the Endothelial Glycocalyx. Anesthesiology
115, 483–491 (2011).
Chappell, D. et al. The Glycocalyx of the Human Umbilical Vein Endothelial Cell:
An Impressive Structure Ex Vivo but Not in Culture. Circ. Res. 104, 1313–1317
(2009).
Chappell, D. et al. TNF-α induced shedding of the endothelial glycocalyx is
prevented by hydrocortisone and antithrombin. Basic Res. Cardiol. 104, 78–89
(2009).
Chiasson, J. L. et al. Diagnosis and treatment of diabetic ketoacidosis and the
hyperglycemic hyperosmolar state. CMAJ 168, 859–66 (2003).
Chignalia, A. Z. et al. the Glycocalyx and Trauma. Shock 45, 338–348 (2016).

51

37.

38.

39.
40.

41.

42.
43.
44.

45.

46.
47.

48.
49.
50.

51.

52.
53.

Chowdhury, B. et al. Hyaluronidase 2 (HYAL2) is expressed in endothelial cells, as
well as some specialized epithelial cells, and is required for normal hyaluronan
catabolism. Histochem. Cell Biol. 145, 53–66 (2016).
Ciarla, M. V. et al. Autoantibodies and endothelial dysfunction in well-controlled,
uncomplicated insulin-dependent diabetes mellitus patients. Atherosclerosis 158,
241–6 (2001).
Cifonelli, J. & Dorfman, A. A colorimetric method for determination of linkage in
hexosamine-containing compounds. J. Biol. Chem. 231, 11–8 (1958).
Clancy, R. M., Leszczynskapiziak, J. & Abramson, S. B. Nitric-Oxide, an
Endothelial-Cell Relaxation Factor, Inhibits Neutrophil Superoxide Anion
Production Via a Direct Action on the Nadph Oxidase. J. Clin. Invest. 90, 1116–
1121 (1992).
Cosentino, F. et al. High Glucose Increases Nitric Oxide Synthase Expression and
Superoxide Anion Generation in Human Aortic Endothelial Cells. Circulation 96,
25–28 (1997).
Csoka, A. B., Frost, G. I. & Stern, R. The six hyaluronidase-like genes in the human
and mouse genomes. Matrix Biol. 20, 499–508 (2001).
Dalton, R. R. et al. Plasma C-Reactive Protein Levels in Severe Diabetic
Ketoacidosis. Ann. Clin. Lab. Sci. 33, 435–442 (2003).
De Caterina, R. et al. Nitric oxide decreases cykotine-induced endothelial
activation. Nitric oxide selectively redeuced endothelial expression of adhesion
molecules and pro inflamatory cytokines. J Clin Invest 96, 60–68 (1995).
De La Motte, C. et al. Platelet-derived hyaluronidase 2 cleaves hyaluronan into
fragments that trigger monocyte-mediated production of proinflammatory
cytokines. Am. J. Pathol. 174, 2254–2264 (2009).
Dechert, T. A. et al. Hyaluronan in human acute and chronic dermal wounds.
Wound Repair Regen. 14, 252–8 (2017).
Delli, A. J. et al. Type 1 diabetes patients born to immigrants to Sweden increase
their native diabetes risk and differ from Swedish patients in HLA types and islet
autoantibodies. Pediatr. Diabetes 11, 513–520 (2010).
DeWitt, D. E. & Hirsch, I. B. Outpatient Insulin Therapy in Type 1 and Type 2
Diabetes Mellitus. JAMA 289, 2254 (2003).
Drake-Holland, A. J. & Noble, M. I. M. Development of the damaged glycocalyx
hypothesis - A review. Cardiovasc. Disord. Med. 3, 388–396 (2018).
Ebong, E. E. et al. Imaging the Endothelial Glycocalyx In Vitro by Rapid
Freezing/Freeze Substitution Transmission Electron Microscopy. Arterioscler.
Thromb. Vasc. Biol. 31, 1908–1915 (2011).
Ebong, E. E., Spray, D. C. & Tarbell, J. M. The Endothelial Glycocalyx In Vitro: Its
Structure and The Role of Heparan Sulfate and Glypican-1 in eNOS Activation by
Flow. Faseb J. 24, 6–7 (2010).
Ernst, S. et al. Enzymatic degradation of glycosaminoglycans. Crit. Rev. Biochem.
Mol. Biol. 30, 387–444 (1995).
Esmon, C. T. Basic mechanisms and pathogenesis of venous thrombosis. Blood
Rev. 23, 225–229 (2009).

52

54.
55.

56.

57.
58.
59.
60.

61.

62.

63.
64.
65.

66.
67.

68.

69.
70.

Esser, P. R. et al. Contact sensitizers induce skin inflammation via ROS production
and hyaluronic acid degradation. PLoS One 7, (2012).
Figueroa, R. E. et al. Study of subclinical cerebral edema in diabetic ketoacidosis by
magnetic resonance imaging T2 relaxometry and apparent diffusion coefficient
maps. Endocr. Res. 31, 345–355 (2005).
Fischer, S. et al. W. H2O2 induces paracellular permeability of porcine brainderived microvascular endothelial cells by activation of the p44/42 MAP kinase
pathway. Eur. J. Cell Biol. 84, 687–697 (2005).
Florian, J. A. et al. Heparan Sulfate Proteoglycan Is a Mechanosensor on
Endothelial Cells. Circ. Res. 93, 136e–142 (2003).
Foster, J. R., Morrison, G. & Fraser, D. D. Diabetic ketoacidosis-associated stroke
in children and youth. Stroke Res. Treat. 2011, (2011).
Frank, P. G. & Lisanti, M. P. Role of caveolin-1 in the regulation of the vascular
shear stress response. J. Clin. Invest. 116, 1222–1225 (2006).
Gao, L. & Lipowsky H. H. Composition of the endothelial glycocalyx and its
relation to its thickness and diffusion of small solutes. Microvasc. Res. 80, 394–401
(2010).
Gauthier, T. W., Davenpeck, K. L. & Lefer, M. Nitric oxide attenuates leukocyteendothelial interaction via P-selectin in splanchnic ischemia-reperfusion. Am. J.
Physiol. 267, G562–G568 (1994).
Gillio-Meina, C., Cepinskas, G., Cecchini, E. L. & Fraser, D. D. Translational
research in pediatrics II: blood collection, processing, shipping, and storage.
Pediatrics 131, 754–66 (2013).
Girish, K. S. & Kemparaju, K. The magic glue hyaluronan and its eraser
hyaluronidase: A biological overview. Life Sci. 80, 1921–1943 (2007).
Giuffrè, L. et al. Monocyte adhesion to activated aortic endothelium: Role of Lselectin and heparan sulfate proteoglycans. J. Cell Biol. 136, 945–956 (1997).
Giugliano, D. et al. Vascular effects of acute hyperglycemia in humans are reversed
by L-arginine. Evidence for reduced availability of nitric oxide during
hyperglycemia. Circulation 95, 1783–90 (1997).
Glaser , N. S. et al. Mechanism of cerebral edema in children with diabetic
ketoacidosis. J. Pediatr. 145, 164–171 (2004).
Goodall, K. J. et al. Soluble heparan sulfate fragments generated by heparanase
trigger the release of pro-inflammatory cytokines through TLR-4. PLoS One 9,
(2014).
Gragnano, F. et al. The Role of von Willebrand Factor in Vascular Inflammation:
From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017, 5620314
(2017).
Graham, G. Diabetes mellitus A Survey of Changes in Treatment During the Last
Fifteen Years. Lancet 232, 121–125 (1938).
Gutierrez, J. A. et al. Femoral central venous catheter-associated deep venous
thrombosis in children with diabetic ketoacidosis. Crit. Care Med. 31, 80–3 (2003).

53

71.

72.

73.
74.
75.

76.
77.
78.
79.

80.

81.
82.

83.

84.
85.
86.

87.
88.

Guzik, T. J. et al. Mechanisms of increased vascular superoxide production in
human diabetes mellitus: Role of NAD(P)H oxidase and endothelial nitric oxide
synthase. Circulation 105, 1656–1662 (2002).
Harada, H. & Takahashi, M. CD44-dependent intracellular and extracellular
catabolism of hyaluronic acid by hyaluronidase-1 and -2. J. Biol. Chem. 282, 5597–
5607 (2007).
Hascall, V. C. et al. Intracellular hyaluronan: a new frontier for inflammation?
Biochim. Biophys. Acta 1673, 3–12 (2004).
Haslinger, B. et al. Hyaluronan fragments induce the synthesis of MCP-1 and IL-8
in cultured human peritoneal mesothelial cells. Cell Tissue Res. 305, 79–86 (2001).
Hayashida, K., Parks, W. C. & Pyong, W. P. Syndecan-1 shedding facilitates the
resolution of neutrophilic inflammation by removing sequestered CXC chemokines.
Blood 114, 3033–3043 (2009).
Haywood-Watson, R. J. et al. Modulation of syndecan-1 shedding after
hemorrhagic shock and resuscitation. PLoS One 6, (2011).
Henry, C. B. S. & Duling, B. R. Permeation of the luminal capillary glycocalyx is
determined by hyaluronan. Am. J. Physiol. Circ. Physiol. 277, H508–H514 (1999).
Hoffman, W. H. et al. Oxidative damage is present in the fatal brain edema of
diabetic ketoacidosis. Brain Res. 1369, 194–202 (2011).
Hoffman, W. H., Stamatovic, S. M. & Andjelkovic, A. V. Inflammatory mediators
and blood brain barrier disruption in fatal brain edema of diabetic ketoacidosis.
Brain Res. 1254, 138–148 (2009).
Hofinger, E. S. et al. Recombinant human hyaluronidase Hyal-1: insect cells versus
Escherichia coli as expression system and identification of low molecular weight
inhibitors. Glycobiology 17, 444–453 (2007).
Huang, L et al. Local injection of high-molecular hyaluronan promotes wound
healing in old rats by increasing angiogenesis. Oncotarget 9, 8241–8252 (2018).
İleri, N. Ş. et al. Evaluation of the Haemostatic System during Ketoacidotic
Deterioration of Diabetes mellitus. Pathophysiol. Haemost. Thromb. 29, 318–325
(1999).
Inoguchi, T. Protein Kinase C-Dependent Increase in Reactive Oxygen Species
(ROS) Production in Vascular Tissues of Diabetes: Role of Vascular NAD(P)H
Oxidase. J. Am. Soc. Nephrol. 14, 227S–232 (2003).
Jiang, D. et al. Regulation of lung injury and repair by Toll-like receptors and
hyaluronan. Nat. Med. 11, 1173–1179 (2005).
Jiang, D., Liang, J. & Noble, P. W. Hyaluronan in Tissue Injury and Repair. Annu.
Rev. Cell Dev. Biol. 23, 435–461 (2007).
Johansson, P. I. et al. High Admission Syndecan-1 Level, A Marker of Endothelial
Glycocalyx Degradation, Is Associated With Inflammation, Protein C Depletion,
Fibrinolysis, and Increased Mortality in Trauma Patients. Ann. Surg. 254, 194–200
(2011).
Katsarou, A. et al. Type 1 diabetes mellitus. Nat. Rev. Dis. Prim. 3, 17016 (2017).
Khan, A. I. et al. Role of CD44 and Hyaluronan in Neutrophil Recruitment. J.
Immunol. 173, 7594–7601 (2004).

54

89.

90.
91.
92.
93.

94.
95.

96.

97.
98.
99.

100.
101.
102.
103.
104.

105.
106.

Kirkman, D. L. et al. Role of mitochondria-derived reactive oxygen species in
microvascular dysfunction in chronic kidney disease. Am. J. Physiol. Physiol. 314,
F423–F429 (2018).
Klempner, M. S. & Styrt, B. Alkalinizing the intralysosomal pH inhibits
degranulation of human neutrophils. J. Clin. Invest. 72, 1793–1800 (1983).
Kolářová, H. et al. Modulation of endothelial glycocalyx structure under
inflammatory conditions. Mediators Inflamm. 2014, (2014).
Kolset, S. O., Reinholt, F. P. & Jenssen, T. Diabetic Nephropathy and Extracellular
Matrix. J. Histochem. Cytochem. 60, 976–986 (2012).
Kondrashova, A. et al. The ‘Hygiene hypothesis’ and the sharp gradient in the
incidence of autoimmune and allergic diseases between Russian Karelia and
Finland. Apmis 121, 478–493 (2013).
Koshiishi, I., Shizari, M. & Underhill, C. B. CD44 can mediate the adhesion of
platelets to hyaluronan. Blood 84, 390–6 (1994).
Kothapalli, D. et al. Differential activation of ERK and Rac mediates the
proliferative and anti-proliferative effects of hyaluronan and CD44. J. Biol. Chem.
283, 31823–31829 (2008).
Krogvold, L. et al. Insulitis and characterisation of infiltrating T cells in surgical
pancreatic tail resections from patients at onset of type 1 diabetes. Diabetologia 59,
492–501 (2016).
Krotz, F. Reactive Oxygen Species: Players in the Platelet Game. Arterioscler.
Thromb. Vasc. Biol. 24, 1988–1996 (2004).
Kuhlmann, C. R. W. et al. Mechanisms of C-reactive protein-induced blood-brain
barrier disruption. Stroke 40, 1458–1466 (2009).
Kwok, J. C. F., Afshari, F., García-Alías, G. & Fawcett, J. W. Proteoglycans in the
central nervous system: plasticity, regeneration and their stimulation with
chondroitinase ABC. Restor. Neurol. Neurosci. 26, 131–45 (2008).
La Torre, D. et al. Decreased cord-blood phospholipids in young age-at-onset type 1
diabetes. Diabetes 62, 3951–3956 (2013).
Lavi, S. et al. Impaired cerebral CO2 vasoreactivity : association with endothelial
dysfunction Am J Physiol Heart Circ Physiol. 291, 1856–1861 (2006).
Lawrence, S. E. et al. Population-based study of incidence and risk factors for
cerebral edema in pediatric diabetic ketoacidosis. J. Pediatr. 146, 688–692 (2005).
Lee-Sayer, S. S. et al. The where, when, how and why of hyaluronan binding by
immune cells. Front. Immunol. 6, 1–12 (2015).
Lefer, A. M. & Ma, X. L. Decreased basal nitric oxide release in
hypercholesterolemia increases neutrophil adherence to rabbit coronary artery
endothelium. Arterioscler. Thromb. Vasc. Biol. 13, 771–776 (1993).
Lemkes, B. A. et al. Hyperglycemia: a prothrombotic factor? J. Thromb. Haemost.
8, 1663–9 (2010).
Lepedda, A. J. et al. Significance of urinary glycosaminoglycans/proteoglycans in
the evaluation of type 1 and type 2 diabetes complications. J. Diabetes
Complications 31, 149–155 (2017).

55

107. Leu, S. W. et al. TLR4 through IFN-ß Promotes Low Molecular Mass HyaluronanInduced Neutrophil Apoptosis. J. Immunol. 186, 556–562 (2011).
108. Levin, D. L. Cerebral edema in diabetic ketoacidosis. Pediatr. Crit. Care Med. 9,
320–329 (2008).
109. Lipscombe, R. J. et al. Interleukin-5 binds to heparin heparan sulfate. A model for
an interaction with extracellular matrix. J.Leukocyte Biol. 63, 342–350 (1998).
110. Liu, G. et al. CD44 sensitivity of platelet activation, membrane scrambling and
adhesion under high arterial shear rates. Thromb. Haemost. 115, 99–108 (2016).
111. Lokeshwar, V. B. & Selzer, M. G. Differences in hyaluronic acid-mediated
functions and signaling in arterial, microvessel, and vein-derived human endothelial
cells. J. Biol. Chem. 275, 27641–9 (2000).
112. Long, B. & Koyfman, A. Emergency Medicine Myths: Cerebral Edema in Pediatric
Diabetic Ketoacidosis and Intravenous Fluids. J. Emerg. Med. 53, 212–221 (2017).
113. Ma, L. et al. Transcranial doppler-based assessment of cerebral autoregulation in
critically Ill children during diabetic ketoacidosis treatment. Pediatr. Crit. Care
Med. 15, 742–749 (2014).
114. Ma, X. L. et al. Diminished basal nitric oxide release after myocardial ischemia and
reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 72,
403–412 (1993).
115. Makino, H. et al. Heparan sulfate proteoglycans are lost in patients with diabetic
nephropathy. Nephron 61, 415–21 (1992).
116. Marcin, J. P., Gosselin, R. & Holland, P. Hypercoagulability Among Pediatric
Patients With Diabetic Ketoacidosis. Pediatr. Crit. Care Med. 14, 325–326 (2013).
117. Marki, A. et al. Role of the endothelial surface layer in neutrophil recruitment. J.
Leukoc. Biol. 98, 503–515 (2015).
118. McDonald, K. K. et al. Glycocalyx degradation induces a proinflammatory
phenotype and increased leukocyte adhesion in cultured endothelial cells under
flow. PLoS One 11, 1–21 (2016).
119. Meng, L. & Gelb, A. W. Regulation of Cerebral Autoregulation by Carbon Dioxide.
Anesthesiology 122, 196–205 (2015).
120. Mine, S. et al. Serum hyaluronan concentration as a marker of angiopathy in
patients with diabetes mellitus. Endocr. J. 53, 761–6 (2006).
121. Minshall, R. D. et al. Caveolin regulation of endothelial function. Am J Physiol
Lung Cell Mol Physiol 285, L1179–83 ST–Caveolin regulation of endothelial
(2003).
122. Mio, K. & Stern, R. Inhibitors of the hyaluronidases. Matrix Biol. 21, 31–37 (2002).
123. Mohamadzadeh, M. et al. Proinflammatory stimuli regulate endothelial hyaluronan
expression and CD44/HA-dependent primary adhesion. J. Clin. Invest. 101, 97–108
(1998).
124. Monslow, J., Govindaraju, P. & Puré, E. Hyaluronan - a functional and structural
sweet spot in the tissue microenvironment. Front. Immunol. 6, 4–10 (2015).
125. Monzon, M. E. et al. Reactive oxygen species and hyaluronidase 2 regulate airway
epithelial hyaluronan fragmentation. J. Biol. Chem. 285, 26126–26134 (2010).

56

126. Mulivor, A. W. & Lipowsky, H. H. Inflammation- and ischemia-induced shedding
of venular glycocalyx. Am. J. Physiol. Heart Circ. Physiol. 286, H1672-80 (2004).
127. Mulivor, A. W. & Lipowsky, H. H. Role of glycocalyx in leukocyte-endothelial cell
adhesion. Am. J. Physiol. - Hear. Circ. Physiol. 283, H1282–H1291 (2002).
128. Mummery, R. S. & Rider, C. C. Characterization of the Heparin-Binding Properties
of IL-6. J. Immunol. 173, 4755–4755 (2004).
129. Nandi, A., Estess, P. & Siegelman, M. Bimolecular Complex between Rolling and
Firm Adhesion Receptors Required for Cell Arrest. Immunity 20, 455–465 (2004).
130. Nandi, A., Estess, P. & Siegelman, M. H. Hyaluronan anchoring and regulation on
the surface of vascular endothelial cells is mediated through the functionally active
form of CD44. J. Biol. Chem. 275, 14939–14948 (2000).
131. Nelson, A., Berkestedt, I. & Bodelsson, M. Circulating glycosaminoglycan species
in septic shock. Acta Anaesthesiol. Scand. 58, 36–43 (2014).
132. Nieuwdorp, M. et al. Endothelial Glycocalyx Damage Coincides With
Microalbuminuria in Type 1 Diabetes. Diabetes 55, 1127–1132 (2006).
133. Nieuwdorp, M. et al. Loss of endothelial glycocalyx during acute hyperglycemia
coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes
55, 480–486 (2006).
134. Nieuwdorp, M. et al. Perturbation of hyaluronan metabolism predisposes patients
with type 1 diabetes mellitus to atherosclerosis. Diabetologia 50, 1288–1293
(2007).
135. Nieuwdorp, M. et al. Tumor necrosis factor-α inhibition protects against endotoxininduced endothelial glycocalyx perturbation. Atherosclerosis 202, 296–303 (2009).
136. Nyenwe, E. A. & Kitabchi, A. E. The evolution of diabetic ketoacidosis: An update
of its etiology, pathogenesis and management. Metabolism. 65, 507–521 (2016).
137. Oemar, B. S. et al. Reduced endothelial nitric oxide synthase expression and
production in human atherosclerosis. Circulation 97, 2494–8 (1998).
138. Omatsu, T. et al. CXCL1/CXCL8 (GROα/IL-8) in human diabetic ketoacidosis
plasma facilitates leukocyte recruitment to cerebrovascular endothelium in vitro.
AJP Endocrinol. Metab. 306, E1077–E1084 (2014).
139. Østerholt, H. C. D. et al. Antioxidant protects against increases in low molecular
weight hyaluronan and inflammation in asphyxiated newborn pigs resuscitated with
100% oxygen. PLoS One 7, (2012).
140. Padberg, J. S. et al. Damage of the endothelial glycocalyx in chronic kidney disease.
Atherosclerosis 234, 335–343 (2014).
141. Pahakis, M. Y. et al. The role of endothelial glycocalyx components in
mechanotransduction of fluid shear stress. Biochem. Biophys. Res. Commun. 355,
228–233 (2007).
142. Pandey, M. S. & Weigel, P. H. A Hyaluronan Receptor for Endocytosis (HARE)
Link Domain N -Glycan Is Required for Extracellular Signal-regulated Kinase
(ERK) and Nuclear Factor-κB (NF-κB) Signaling in Response to the Uptake of
Hyaluronan but Not Heparin, Dermatan Sulfate, or Acetylated. J. Biol. Chem. 289,
21807–21817 (2014).

57

143. Pandey, M. S. et al. The hyaluronan receptor for endocytosis (HARE) activates NFκB-mediated gene expression in response to 40-400-kDa, but not smaller or larger,
hyaluronans. J. Biol. Chem. 288, 14068–14079 (2013).
144. Paneni, F. et al. Diabetes and vascular disease: Pathophysiology, clinical
consequences, and medical therapy: Part i. Eur. Heart J. 34, 2436–2446 (2013).
145. Patel, A. et al. Incidence, Trends, and Outcomes of Cerebral Edema Among
Children With Diabetic Ketoacidosis in the United States. Clin. Pediatr. (Phila). 55,
943–951 (2016).
146. Pauloin, T. et al. High molecular weight hyaluronan decreases UVB-induced
apoptosis and inflammation in human epithelial corneal cells. Mol. Vis. 15, 577–583
(2009).
147. Pavan, M. et al. A new potential spreading factor: Streptomyces koganeiensis
hyaluronidase. A comparative study with bovine testes hyaluronidase and
recombinant human hyaluronidase of the HA degradation in ECM. Biochim Biophys
Acta. 1680, 661-668 (2016).
148. Piazza, G. et al. Venous thromboembolism in patients with diabetes mellitus. Am. J.
Med. 125, 709–16 (2012).
149. Polgar, J., Matuskova, J. & Wagner, D. D. The P-selectin, tissue factor, coagulation
triad. J. Thromb. Haemost. 3, 1590–1596 (2005).
150. Quillard, T. et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and
detachment: Implications for superficial erosion. Eur. Heart J. 36, 1394–1404
(2015).
151. Rahbar, E. et al. Endothelial glycocalyx shedding and vascular permeability in
severely injured trauma patients. J. Transl. Med. 13, 117 (2015).
152. Redon, J. & Rodicio, J. L. Microalbuminuria in type 1 diabetes mellitus. J.
Hypertens. 22, 1425–8 (2004).
153. Redondo, M. J. et al. Concordance for islet autoimmunity among monozygotic
twins. N. Engl. J. Med. 359, 2849–50 (2008).
154. Reitsma, S. et al. The endothelial glycocalyx: Composition, functions, and
visualization. Pflugers Arch. Eur. J. Physiol. 454, 345–359 (2007).
155. Rewers, A. et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus
in youth: The search for diabetes in youth study. Pediatrics 121, E1258–E1266
(2008).
156. Roberts, J. S. et al. Cerebral hyperemia and impaired cerebral autoregulation
associated with diabetic ketoacidosis in critically ill children. Crit. Care Med. 34,
2217–2223 (2006).
157. Romano, M. et al. Endothelial Perturbation in Children and Adolescents With Type
1 Diabetes: Association with markers of the inflammatory reaction. Diabetes Care
24, 1674–1678 (2001).
158. Rose, K. L. et al. Simulated diabetic ketoacidosis therapy in vitro elicits brain cell
swelling via sodium-hydrogen exchange and anion transport. Am. J. Physiol. Endocrinol. Metab. 309, E370–E379 (2015).
159. Sakamoto, T. et al. Rapid Change of Platelet Aggregability in Acute
Hyperglycemia. Thromb. Haemost. 83, 475–479 (2000).

58

160. Salek-Ardakani, S. et al. Heparin and heparan sulfate bind interleukin-10 and
modulate its activity. Blood 96, 1879–1888 (2000).
161. Schäfer, A. et al. Rapid Regulation of Platelet Activation in Vivo by Nitric Oxide.
Circulation 109, 1819–1822 (2004).
162. Scheibner, K. A. et al. Hyaluronan Fragments Act as an Endogenous Danger Signal
by Engaging TLR2. J. Immunol. 177, 1272–1281 (2006).
163. Siiskonen, H. Hyaluronan and hyaluronan synthases. Publications of the University
of Eastern Finland, Faculty of Health Sciences. (2013).
164. Simeonovic, C. J. et al. Heparanase and autoimmune diabetes. Front. Immunol. 4,
1–7 (2013).
165. Simon Davis, D. A. & Parish, C. R. Heparan sulfate: A ubiquitous
glycosaminoglycan with multiple roles in immunity. Front. Immunol. 4, 1–7 (2013).
166. Simon-Walker, R. et al. Glycocalyx-inspired nitric oxide-releasing surfaces reduce
platelet adhesion and activation on titanium. ACS Biomater. Sci. Eng. 3, 68–77
(2017).
167. Singleton, P. A. & Bourguignon, L. Y. W. CD44 interaction with ankyrin and IP3
receptor in lipid rafts promotes hyaluronan-mediated Ca2+signaling leading to nitric
oxide production and endothelial cell adhesion and proliferation. Exp. Cell Res. 295,
102–118 (2004).
168. Slevin, M., Kumar, S. & Gaffney, J. Angiogenic oligosaccharides of hyaluronan
induce multiple signaling pathways affecting vascular endothelial cell mitogenic
and wound healing responses. J. Biol. Chem. 277, 41046–41059 (2002).
169. Sokol, M. C. et al. Impact of medication adherence on hospitalization risk and
healthcare cost. Med. Care 43, 521–30 (2005).
170. Song, J. W. et al. Therapeutic Restoration of Endothelial Glycocalyx in Sepsis. J.
Pharmacol. Exp. Ther. jpet.116.239509 (2017). doi:10.1124/jpet.116.239509
171. Srinivas, M. et al. Diabetic Ketoacidosis in Children : A Systematic Review. (2016).
172. Svennevig, K., Kolset, S. O. & Bangstad, H.-J. Increased syndecan-1 in serum is
related to early nephropathy in type 1 diabetes mellitus patients. Diabetologia 49,
2214–6 (2006).
173. Tarbell, J. M. & Ebong, E. E. The Endothelial Glycocalyx: A Mechano-Sensor and
-Transducer. 1, 1–6 (2012).
174. Tarbell, J. M. & Pahakis, M. Y. Mechanotransduction and the glycocalyx. J. Intern.
Med. 259, 339–350 (2006).
175. Taylor, K. R. et al. Hyaluronan Fragments Stimulate Endothelial Recognition of
Injury through TLR4. J. Biol. Chem. 279, 17079–17084 (2004).
176. Taylor, K. R. et al. Recognition of Hyaluronan Released in Sterile Injury Involves a
Unique Receptor Complex Dependent on Toll-like Receptor 4, CD44, and MD-2. J.
Biol. Chem. 282, 18265–18275 (2007).
177. Teder, P. et al. Resolution of lung inflammation by CD44. Science 296, 155–8
(2002).
178. Teien, A. N., Abildgaard, U. & Höök, M. The anticoagulant effect of heparan
sulfate and dermatan sulfate. Thromb. Res. 8, 859–867 (1976).

59

179. Toda, N., Ayajiki, K. & Okamura, T. Cerebral Blood Flow Regulation by Nitric
Oxide: Recent Advances. Pharmacol. Rev. 61, 62–97 (2009).
180. Tornese, G. et al. Glycemic Control and Excess Mortality in Type 1 Diabetes. N.
Engl. J. Med. 372, 879–881 (2015).
181. Torres Filho, I. P. et al. Plasma syndecan-1 and heparan sulfate correlate with
microvascular glycocalyx degradation in hemorrhaged rats after different
resuscitation fluids. Am. J. Physiol. - Hear. Circ. Physiol. 310, H1468–H1478
(2016).
182. Toyoshima, M. Human Heparanase. Biochemistry 274, 24153–24160 (1999).
183. Tran, T. H. et al. Coagulation assessment in children with diabetic ketoacidosis.
Pediatr. Crit. Care Med. 14, 256–60 (2013).
184. Tsao, C.-M., Ho, S.-T. & Wu, C.-C. Coagulation abnormalities in sepsis. Acta
Anaesthesiol. Taiwanica 53, 16–22 (2015).
185. Udabage, L. et al. Inhibition of hyaluronan degradation by dextran sulphate
facilitates characterisation of hyaluronan synthesis: An in vitro and in vivo study.
Glycoconj. J. 20, 461–471 (2004).
186. Van der Meulen, J. A., Klip, A. & Grinstein, S. Possible mechanism for cerebral
oedema in diabetic ketoacidosis. Lancet (London, England) 2, 306–8 (1987).
187. Varatharaj, A. & Galea, I. The blood-brain barrier in systemic inflammation. Brain.
Behav. Immun. 60, 1–12 (2017).
188. Vavilala, M. S. et al. Change in blood– brain barrier permeability during pediatric
diabetic ketoacidosis treatment. Pediatr Crit Care Med 11, 332–338 (2010).
189. Vendrov, A. E. et al. NADPH oxidases regulate CD44 and hyaluronic acid
expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.
J. Biol. Chem. 285, 26545–26557 (2010).
190. Verma, S. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide
production and inhibits angiogenesis. Circulation 106, 913–919 (2002).
191. Vernier, R. L. et al. Heparan sulfate proteoglycan in the glomerular basement
membrane in type 1 diabetes mellitus. Kidney Int. 41, 1070–1080 (1992).
192. Vink, H., Constantinescu, A. A. & Spaan, J. A. Oxidized lipoproteins degrade the
endothelial surface layer : implications for platelet-endothelial cell adhesion.
Circulation 101, 1500–2 (2000).
193. Voyvodic, P. L. et al. Loss of syndecan-1 induces a pro-inflammatory phenotype in
endothelial cells with a dysregulated response to atheroprotective flow. J. Biol.
Chem. 289, 9547–9559 (2014).
194. Wang, W., Wang, J. & Li, F. Hyaluronidase and Chondroitinase. Advs Exp.
Medicine and Biology. 925, 75–87 (2017).
195. Wang, Y. Z. et al. CD44 mediates oligosaccharides of hyaluronan-induced
proliferation, tube formation and signal transduction in endothelial cells. Exp. Biol.
Med. 236, 84–90 (2011).
196. Webb, L. M. et al. Binding to heparan sulfate or heparin enhances neutrophil
responses to interleukin 8. Proc. Natl. Acad. Sci. 90, 7158–7162 (1993).
197. Weitz, J. I. Heparan sulfate: Antithrombotic or not? J. Clin. Invest. 111, 952–954
(2003).

60

198. West, D. C. & Kumar, S. The effect of hyaluronate and its oligosaccharides on
endothelial cell proliferation and monolayer integrity. Exp. Cell Res. 183, 179–196
(1989).
199. Wink, D. A. et al. Nitric oxide and redox mechanisms in the immune response. J.
Leukoc. Biol. 89, 873–891 (2011).
200. Wolfsdorf, J., Glaser, N. & Sperling, M. A. Diabetic Ketoacidosis in Infants,
Children, and Adolescents: A consensus statement from the American Diabetes
Association. Diabetes Care 29, 1150–1159 (2006).
201. Wolny, P. M. et al. Analysis of CD44-hyaluronan interactions in an artificial
membrane system: Insights into the distinct binding properties of high and low
molecular weight hyaluronan. J. Biol. Chem. 285, 30170–30180 (2010).
202. Woo, M. et al. Dynamic regulation of plasma matrix metalloproteinases in human
diabetic ketoacidosis. Pediatr. Res. 79, 295–300 (2016).
203. Woo, M. et al. Elevated Leukocyte Azurophilic Enzymes in Human Diabetic
Ketoacidosis Plasma Degrade Cerebrovascular Endothelial Junctional Proteins.
Crit. Care Med. 44, e846–e853 (2016).
204. Woo, M. Regulation of Leukocyte-Derived Matrix Metalloproteinases and
Azurophilic Enzymes in Human Diabetic Ketoacidosis. Electronic Thesis and
Dissertation Repository. 2869. (2015).
205. Xu, C. et al. Hyaluronan ameliorates LPS-induced acute lung injury in mice via
Toll-like receptor (TLR) 4-dependent signaling pathways. Int. Immunopharmacol.
28, 1050–1058 (2015).
206. Yamada, S. Biochemical Roles of Eukaryotic Cell Surface Macromolecules. 842,
185–197 (2015).
207. Yang, C. et al. The high and low molecular weight forms of hyaluronan have
distinct effects on CD44 clustering. J. Biol. Chem. 287, 43094–43107 (2012).
208. Yuan, S. Y. Protein kinase signaling in the modulation of microvascular
permeability. Vascul. Pharmacol. 39, 213–223 (2002).
209. Zeng, Y. et al. The structural stability of the endothelial glycocalyx after enzymatic
removal of glycosaminoglycans. PLoS One 7, 1-14 (2012).
210. Zhu, J. et al. Glycocalyx degradation leads to blood–brain barrier dysfunction and
brain edema after asphyxia cardiac arrest in rats. J. Cereb. Blood Flow Metab.
(2017).
211. Ziegler, A. G. et al. Autoantibody appearance and risk for development of
childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis
of the German BABYDIAB Study. Diabetes 48, 460–8 (1999).
212. Ziegler, A. G. et al. Seroconversion to Multiple Islet Autoantibodies and Risk of
Progression to Diabetes in Children. JAMA 309, 2473 (2013).
213. Zou, M.-H., Cohen, R. A. & Ullrich, V. Peroxynitrite and Vascular Endothelial
Dysfunction in Diabetes Mellitus. Endothelium 11, 89–97 (2004).

61

Appendices
As there was increased HA shedding found in the plasma of DKA patients,
HYALase activity was also measured to quantify if any differences in HYALase activity
can be detected between the plasma of insulin-controlled T1DM (CON) and DKA patients.
The obtained data indicates that there were no significant differences in the HYALase
activity of CON and DKA patients. Important to note, we observed a slight trend of
increased HYALase activity in the plasmas of DKA patients (Suppl. Figure 1, P = 0.087, n
= 25). A larger sample analysis may be necessary to determine statistical significance.

Supplementary Figure 1. Plasma HYALase activity in insulin-controlled T1DM (CON)
and DKA patients.
Data is presented as mean g/ml + SEM. Assays were done in triplicate (n = 25/group) and
an unpaired t-test was used to determine significance (P < 0.05). No significant differences
were found (P = 0.087), however there is a trend of increased HYALase activity in DKA
plasma compared to CON.
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Supernatents of the in vitro model HBMEC model were tested after changing the
cells in HBSS to determine if there were any free floating HA shed into the medium (Suppl.
Figure 2). As HYALase was left in the medium, any free floating HA would have been
cleaved to fragments below the detectable limit of the HA ELISA kit, indicating that in
both conditions, HA was present on the cells and HYALase was capable of cleaving HA
fragments to molecular weights below 45 kDA.

Supplementary Figure 2. HA detected by ELISA in Supernatents of HBMEC monolayers
with or without HYALase treatment.
The detectable range of HA on the ELISA kit was >45 kDa and all of the HYALase
supernatents had no detectable HA via ELISA, as the size most likely fell below the
detection limit. Data is shown as mean + SEM. A non-parametric Mann-Whitney test was
used to determine any significant differences (P<0.001, n = 8).
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Supplementary Figure 3. Densitometric quantification of ERK1 phosphorylation in
HBMEC stimulated with HYALase
The ratio between phosphorylation of ERK1 and total ERK1 levels were calculated and
expressed as a percentage. A Kruskal-Wallis test was done to determine no significant
differences in density of HYALase treated wells compared to control conditions at 30 min
and 2 hrs. Data is shown as mean % + SEM phosphorylation of ERK1. To correct for
multiple comparisons, Dunn’s test was used to determine significance (*P < 0.05).
Comparisons were only made according to each respective timed control (30 min, n = 7; 2
hrs, n = 9)
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Permeability of the in vitro HBMEC model was tested through 2 separate ways,
using an electric cell-substrate impedance sensing system (ECIS) (Suppl. Figure 4) and a
trans-well system (Suppl. Figure 5) under HYALase and LMW HA treated conditions. We
wanted to determine if shedding of the HA or proinflammatory LMW HA would increase
permeability, leading to a role in CE. No changes in permeability were found. This is found
to be consistent in the literature, where the trans-endothelial barrier is maintained, but the
surface layer may be thinner51.

Supplementary Figure 4. Resistance Measurements of LMW HA or HYALase on naïve
HBMEC cells via Electric Cell-substrate Impedance Sensing (ECIS)
Each condition had its own control well. Data is shown as % of baseline resistance from
before treatment compared to after 2 hr treatment of LMW HA (100 g/ml), HYALase
(200 U/ml), or control media. A non-parametric, Mann-Whitney test was used to determine
any significant differences. There were no significant differences in resistance changes
between each treatment to its respective control (LMW HA: n = 4, HYALase: n = 3).
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Supplementary Figure 5. HBMEC Permeability after Heparinase and/or HYALase
treatment determined via Fluorescein isothiocyanate-Dextran
Data is presented as mean fluorescence + SEM. HBMEC monolayer permeability was
determined by the amount of fluorescent 3k-Dextran in the lower chamber of the transwell
after 2 hr treatments. A non-parametric, Kruskal-Wallis test was used to determine any
significant differences (n = 4). No significant differences were found between control and
any of the enzyme treatments.
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Adhesion and rolling of PMNs were tested after HYALase and/or heparinase
treatment on naïve HBMEC cells to determine if glycocalyx removal would be able to
induce endothelial activation. First, we applied the treatment only to naïve HBMEC cells to
work with stimulating one compartment at a time (Suppl. Figure 6). Next we stimulated
both compartments that would be exposed to glycocalyx shedding (Suppl. Figure 7). In
both experiments, treatments did not induce a functional endothelial activation state.

A

Adhesion of PMNs
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B

Rolling of PMNs

Supplementary Figure 6. PMN adhesion and rolling after treatment of HYALase and/or
Heparinase on naïve HBMEC monolayers.
Data is presented as mean PMNs/area + SEM. A non-parametric, Kruskal-Wallis test was
used to determine any significant differences. A. Amount of PMN adhesion on HBMEC
monolayers, averaged over 5 randomly selected areas. There were no significant
differences between the enzyme treatments and control (HYALase: n = 10,
Heparinase/Heparinase with HYALase: n = 5). B. Amount of PMN rolling on HBMEC
monolayers over 5 minutes after treatments. Outliers greater than 2 standard deviations
were discarded. There were no significant differences between the enzyme treatments and
control (n = 4)
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Supplementary Figure 7. PMN adhesion and rolling after treatment of HYALase on naïve
HBMEC monolayers and PMNs.
Data is presented as mean PMNs/area + SEM. Naïve HBMEC monolayers were stimulated
for 2 hrs with HYALase, while PMNs were stimulated with HYALase 5 min before
perfusion. To determine statistical significance, a Mann-Whitney test applied. A. Amount
of PMN adhesion on HBMEC monolayers, averaged over 5 randomly selected areas. There

69

were no significant differences in PMN adhesion between HYALase and control (CON: n =
7, HYAL n = 6). B. Amount of PMN rolling on HBMEC monolayers over 5 minutes after
treatments. There were no significant differences between HYALase and control (n = 7).
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